

REFINITIV

DELTA REPORT

10-Q

SRDX - SURMODICS INC

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - DECEMBER 31, 2023

The following comparison report has been automatically generated

TOTAL DELTAS	723
--------------	-----

CHANGES	151
---------	-----

DELETIONS	257
-----------	-----

ADDITIONS	315
-----------	-----

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~December~~ March 31, 20232024

or

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 0-23837

Surmodics, Inc.

(Exact name of registrant as specified in its charter)

MINNESOTA

(State or other jurisdiction of incorporation or organization)

41-1356149

(I.R.S. Employer Identification No.)

9924 West 74th Street, Eden Prairie, Minnesota 55344

(Address of principal executive offices) (Zip Code)

(952) 500-7000

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, \$0.05 par value	SRDX	Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☒

Non-accelerated filer ☐ Smaller reporting company ☐ Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The number of shares of the registrant's Common Stock, \$0.05 par value per share, as of **January 29, 2024** **April 26, 2024** was **14,236,000** **14,260,000**.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1.	Unaudited Condensed Consolidated Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	19
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	28 29
Item 4.	Controls and Procedures	29 30

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	30 31
Item 1A.	Risk Factors	30 31
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	30 31
Item 3.	Defaults Upon Senior Securities	30 31
Item 4.	Mine Safety Disclosures	30 31
Item 5.	Other Information	30 31
Item 6.	Exhibits	31 32

<u>SIGNATURES</u>	32 33
--------------------------	--------------

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1. Unaudited Condensed Consolidated Financial Statements

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

	December 31, 2023	September 30, 2023	March 31, 2024	September 30, 2023
(In thousands, except per share data)	(Unaudited)		(Unaudited)	
ASSETS				
Current Assets:				
Cash and cash equivalents	\$ 23,355	\$ 41,419	\$ 33,030	\$ 41,419
Available-for-sale securities	11,819	3,933	7,909	3,933
Accounts receivable, net of allowances of \$86 and \$80 as of December 31, 2023 and September 30, 2023, respectively	12,919	10,850		
Accounts receivable, net of allowances of \$107 and \$80 as of March 31, 2024 and September 30, 2023, respectively	12,319	10,850		
Contract assets	9,178	7,796	10,650	7,796
Inventories, net	14,438	14,839		
Inventories	15,405	14,839		
Income tax receivable	361	491	746	491
Prepays and other	7,738	7,363	4,204	7,363
Total Current Assets	79,808	86,691	84,263	86,691
Property and equipment, net	25,563	26,026	25,718	26,026
Intangible assets, net	26,213	26,206	24,784	26,206
Goodwill	44,283	42,946	43,576	42,946
Other assets	4,373	3,864	4,464	3,864
Total Assets	\$ 180,240	\$ 185,733	\$ 182,805	\$ 185,733
LIABILITIES AND STOCKHOLDERS' EQUITY				
Current Liabilities:				
Accounts payable	\$ 2,581	\$ 2,993	\$ 3,186	\$ 2,993
Accrued liabilities:				
Compensation	4,079	10,139	6,245	10,139
Accrued other	5,809	6,444	5,017	6,444
Deferred revenue	4,008	4,378	4,749	4,378
Total Current Liabilities	16,477	23,954	19,197	23,954
Long-term debt, net	29,443	29,405	29,480	29,405
Deferred revenue, less current portion	1,648	2,400	—	2,400
Deferred income taxes	1,992	2,004	1,857	2,004
Other long-term liabilities	8,530	8,060	8,321	8,060
Total Liabilities	58,090	65,823	58,855	65,823
Commitments and Contingencies (Note 11)				
Stockholders' Equity:				
Series A Preferred stock — \$.05 par value, 450 shares authorized; no shares issued and outstanding	—	—	—	—

Common stock — \$.05 par value, 45,000 shares authorized; 14,235 and 14,155 shares issued and outstanding as of December 31, 2023 and September 30, 2023, respectively	712	708		
Common stock — \$.05 par value, 45,000 shares authorized; 14,260 and 14,155 shares issued and outstanding as of March 31, 2024 and September 30, 2023, respectively	713	708		
Additional paid-in capital	37,621	36,706	40,271	36,706
Accumulated other comprehensive loss	(2,652)	(4,759)	(3,750)	(4,759)
Retained earnings	86,469	87,255	86,716	87,255
Total Stockholders' Equity	122,150	119,910	123,950	119,910
Total Liabilities and Stockholders' Equity	\$ 180,240	\$ 185,733	\$ 182,805	\$ 185,733

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

	Three Months Ended December 31,		Three Months Ended March 31,		Six Months Ended March 31,	
	2023	2022	2024	2023	2024	2023
<i>(In thousands, except per share data)</i>	<i>(Unaudited)</i>		<i>(Unaudited)</i>		<i>(Unaudited)</i>	
Revenue:						
Product sales	\$ 18,827	\$ 14,234	\$ 18,099	\$ 15,350	\$ 36,926	\$ 29,584
Royalties and license fees	9,179	8,765	11,411	9,429	20,590	18,194
Research, development and other	2,546	1,934	2,448	2,419	4,994	4,353
Total revenue	30,552	24,933	31,958	27,198	62,510	52,131
Operating costs and expenses:						
Product costs	8,803	5,267	7,101	5,738	15,904	11,005
Research and development	8,664	12,743	10,229	12,924	18,893	25,667
Selling, general and administrative	12,537	13,236	13,093	12,967	25,630	26,203
Acquired intangible asset amortization	870	913	876	867	1,746	1,780
Restructuring expense	—	1,282	—	1,282		
Contingent consideration expense	—	3	—	3	—	6
Total operating costs and expenses	30,874	32,162	31,299	33,781	62,173	65,943
Operating loss	(322)	(7,229)				
Other expense:						
Operating income (loss)	659	(6,583)	337	(13,812)		
Other expense, net:						
Interest expense, net	(896)	(826)	(881)	(884)	(1,777)	(1,710)
Foreign exchange loss	(45)	(125)	(72)	(75)	(117)	(200)
Investment income, net	539	172	460	177	999	349

Other expense, net	(402)	(779)	(493)	(782)	(895)	(1,561)
Loss before income taxes	(724)	(8,008)				
Income tax (expense) benefit	(62)	165				
Net loss	<u>\$ (786)</u>	<u>\$ (7,843)</u>				
Income (loss) before income taxes	166	(7,365)	(558)	(15,373)		
Income tax benefit (expense)	81	(368)	19	(203)		
Net income (loss)	<u>\$ 247</u>	<u>\$ (7,733)</u>	<u>\$ (539)</u>	<u>\$ (15,576)</u>		
Basic net loss per share	\$ (0.06)	\$ (0.56)				
Diluted net loss per share	\$ (0.06)	\$ (0.56)				
Basic net income (loss) per share	\$ 0.02	\$ (0.55)	\$ (0.04)	\$ (1.11)		
Diluted net income (loss) per share	\$ 0.02	\$ (0.55)	\$ (0.04)	\$ (1.11)		
Weighted average number of shares outstanding:						
Basic	14,102	13,983	14,152	14,030	14,127	14,010
Diluted	14,102	13,983	14,182	14,030	14,127	14,010

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

[TABLE OF CONTENTS](#)

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Comprehensive (Loss) Income (Loss)

	Three Months Ended December 31,		Three Months Ended March 31,		Six Months Ended March 31,	
	2023	2022	2024	2023	2024	2023
<i>(In thousands)</i>	<i>(Unaudited)</i>		<i>(Unaudited)</i>		<i>(Unaudited)</i>	
Net loss	\$ (786)	\$ (7,843)				
Other comprehensive income:						
Net income (loss)	\$ 247	\$ (7,733)	\$ (539)	\$ (15,576)		
Other comprehensive (loss) income:						
Derivative instruments:						
Unrealized net loss	(620)	(444)				
Unrealized net gain (loss)	426	(304)	(194)	(748)		
Net (gain) loss reclassified to earnings	(62)	31	(62)	(11)	(124)	20
Net changes related to available-for-sale securities, net of tax	(8)	—	2	—	(6)	—
Foreign currency translation adjustments	2,797	5,670	(1,464)	1,118	1,333	6,788
Other comprehensive income	<u>2,107</u>	<u>5,257</u>				

Comprehensive income (loss)	\$ 1,321	\$ (2,586)		
Other comprehensive (loss) income	(1,098)	803	1,009	6,060
Comprehensive (loss) income	\$ (851)	\$ (6,930)	\$ 470	\$ (9,516)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Stockholders' Equity

(In thousands)	Three Months Ended March 31, 2024 and 2023					
	(Unaudited)		Accumulated			Total Stockholders' Equity
			Additional	Other	Retained	
	Common Stock		Paid-In	Comprehensive	Earnings	
	Shares	Amount	Capital	Loss		
Balance at December 31,						
2023	14,235	\$ 712	\$ 37,621	\$ (2,652)	\$ 86,469	\$ 122,150
Net income	—	—	—	—	247	247
Other comprehensive loss, net of tax	—	—	—	(1,098)	—	(1,098)
Issuance of common stock	19	1	449	—	—	450
Common stock options exercised, net	6	1	80	—	—	81
Purchase of common stock to pay employee taxes	—	(1)	(5)	—	—	(6)
Stock-based compensation	—	—	2,126	—	—	2,126
Balance at March 31,						
2024	14,260	\$ 713	\$ 40,271	\$ (3,750)	\$ 86,716	\$ 123,950
Balance at December 31,						
2022	14,126	\$ 706	\$ 30,224	\$ (4,617)	\$ 80,948	\$ 107,261
Net loss	—	—	—	—	(7,733)	(7,733)
Other comprehensive income, net of tax	—	—	—	803	—	803
Issuance of common stock	9	1	452	—	—	453
Common stock options exercised, net	—	—	3	—	—	3

Purchase of common stock to pay employee taxes	(1)	—	(15)	—	—	(15)
Stock-based compensation	—	—	1,782	—	—	1,782
Balance at March 31, 2023	<u>14,134</u>	<u>\$ 707</u>	<u>\$ 32,446</u>	<u>\$ (3,814)</u>	<u>\$ 73,215</u>	<u>\$ 102,554</u>

(In thousands)	Three Months Ended December 31, 2023 and 2022						Six Months Ended March 31, 2024 and 2023					
	(Unaudited)		Accumulated				(Unaudited)		Accumulated			
			Additional	Other	Total				Additional	Other	Total	
	Common Stock		Paid-In	Comprehensive	Retained	Stockholders'	Common Stock		Paid-In	Comprehensive	Retained	Stockholders'
	Shares	Amount	Capital	Loss	Earnings	Equity	Shares	Amount	Capital	Loss	Earnings	Equity
Balance at September 30, 2023	14,155	\$ 708	\$ 36,706	\$ (4,759)	\$ 87,255	\$ 119,910	14,155	\$ 708	\$ 36,706	\$ (4,759)	\$ 87,255	\$ 119,910
Net loss	—	—	—	—	(786)	(786)	—	—	—	—	(539)	(539)
Other comprehensive income, net of tax	—	—	—	2,107	—	2,107	—	—	—	1,009	—	1,009
Issuance of common stock	102	5	(5)	—	—	—	121	6	444	—	—	450
Common stock options exercised, net	7	—	39	—	—	39	13	1	119	—	—	120
Purchase of common stock to pay employee taxes	(29)	(1)	(1,087)	—	—	(1,088)	(29)	(2)	(1,092)	—	—	(1,094)
Stock-based compensation	—	—	1,968	—	—	1,968	—	—	4,094	—	—	4,094
Balance at December 31, 2023	<u>14,235</u>	<u>\$ 712</u>	<u>\$ 37,621</u>	<u>\$ (2,652)</u>	<u>\$ 86,469</u>	<u>\$ 122,150</u>						
Balance at March 31, 2024	<u>14,260</u>	<u>\$ 713</u>	<u>\$ 40,271</u>	<u>\$ (3,750)</u>	<u>\$ 86,716</u>	<u>\$ 123,950</u>						
Balance at September 30, 2022	14,029	\$ 701	\$ 28,774	\$ (9,874)	\$ 88,791	\$ 108,392	14,029	\$ 701	\$ 28,774	\$ (9,874)	\$ 88,791	\$ 108,392
Net loss	—	—	—	—	(7,843)	(7,843)	—	—	—	—	(15,576)	(15,576)
Other comprehensive income, net of tax	—	—	—	5,257	—	5,257	—	—	—	6,060	—	6,060
Issuance of common stock	103	5	(5)	—	—	—	112	6	447	—	—	453
Common stock options exercised, net	17	1	346	—	—	347	17	1	349	—	—	350
Purchase of common stock to pay employee taxes	(23)	(1)	(856)	—	—	(857)	(24)	(1)	(871)	—	—	(872)
Stock-based compensation	—	—	1,965	—	—	1,965	—	—	3,747	—	—	3,747
Balance at December 31, 2022	<u>14,126</u>	<u>\$ 706</u>	<u>\$ 30,224</u>	<u>\$ (4,617)</u>	<u>\$ 80,948</u>	<u>\$ 107,261</u>						

Balance at March 31,							
2023	14,134	\$ 707	\$ 32,446	\$ (3,814)	\$ 73,215	\$ 102,554	

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Surmodics, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

	Three Months Ended December 31,		Six Months Ended March 31,	
	2023	2022	2024	2023
	(Unaudited)		(Unaudited)	
(In thousands)				
Operating Activities:				
Net loss	\$ (786)	\$ (7,843)	\$ (539)	\$ (15,576)
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization	2,333	2,122	4,429	4,214
Stock-based compensation	1,968	1,965	4,094	3,747
Noncash lease expense	183	159	397	321
Amortization of debt issuance costs	76	78	144	182
Provision for credit losses	6	59	27	121
Deferred taxes	(97)	(107)	(189)	(217)
Other	(123)	78	(268)	106
Change in operating assets and liabilities:				
Accounts receivable and contract assets	(3,430)	546	(4,337)	(2,346)
Inventories	401	(905)	(565)	(1,948)
Prepays and other	(788)	(1,857)	2,740	(1,582)
Accounts payable	(428)	(1,254)	4	279
Accrued liabilities	(7,084)	(4,700)	(5,007)	(4,064)
Income taxes	99	2,218	(279)	2,629
Deferred revenue	(1,122)	(1,361)	(2,028)	(2,493)
Net cash used in operating activities	(8,792)	(10,802)	(1,377)	(16,627)
Investing Activities:				
Purchases of property and equipment	(720)	(977)	(1,991)	(1,700)
Purchases of available-for-sale securities	(9,750)	—	(13,682)	—
Maturities of available-for-sale securities	2,000	—	10,000	—
Net cash used in investing activities	(8,470)	(977)	(5,673)	(1,700)
Financing Activities:				
Payments of short-term borrowings	—	(10,000)	—	(10,000)

Proceeds from issuance of long-term debt	—	29,664	—	29,664
Payments of debt issuance costs	—	(353)	—	(611)
Issuance of common stock	39	347	570	803
Payments for taxes related to net share settlement of equity awards	(1,088)	(858)	(1,093)	(872)
Payments for acquisition of in-process research and development	(931)	(978)		
Net cash (used in) provided by financing activities	(1,049)	18,800	(1,454)	18,006
Effect of exchange rate changes on cash	247	411	115	503
Net change in cash and cash equivalents	(18,064)	7,432	(8,389)	182
Cash and Cash Equivalents:				
Beginning of period	41,419	18,998	41,419	18,998
End of period	\$ 23,355	\$ 26,430	\$ 33,030	\$ 19,180
Supplemental Information:				
Cash paid for income taxes	\$ —	\$ 5	\$ 338	\$ 10
Cash paid for interest	779	660	1,518	1,393
Noncash investing and financing activities:				
Acquisition of property and equipment	43	150	227	355
Right-of-use assets obtained in exchange for operating lease liabilities	845	—	845	—

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

Surmodics, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
Period Ended December 31, 2023 March 31, 2024
(Unaudited)

1. Organization

Description of Business

Surmodics, Inc. and subsidiaries (referred to as “Surmodics,” the “Company,” “we,” “us,” “our” and other like terms) is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic (“IVD”) immunoassay tests and microarrays. Surmodics develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota.

Basis of Presentation and Principles of Consolidation

The accompanying unaudited condensed consolidated financial statements include all accounts and wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP"). All intercompany transactions have been eliminated. The Company operates on a fiscal year ending on September 30. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"), the Company has omitted footnote disclosures that would substantially duplicate the disclosures contained in the audited consolidated financial statements of the Company. These unaudited condensed consolidated financial statements should be read together with the audited consolidated financial statements for the fiscal year ended September 30, 2023, and notes thereto included in our Annual Report on Form 10-K as filed with the SEC.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates. The results of operations for the three and six months ended December 31, 2023 March 31, 2024 are not necessarily indicative of the results that may be expected for the entire 2024 fiscal year.

New Accounting Pronouncements

Not Yet Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, *Segment Reporting: Improvements to Reportable Segment Disclosures*. This guidance requires disclosure of incremental segment information on an annual and interim basis. This amendment is effective for our fiscal year ending September 30, 2025 and interim periods within our fiscal year ending September 30, 2026. We are currently assessing the impact of this guidance on our disclosures.

In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes: Improvements to Income Tax Disclosures*. This guidance requires consistent categories and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment is effective for our fiscal year ending September 30, 2026 and interim periods within our fiscal year ending September 30, 2027. We are currently assessing the impact of this guidance on our disclosures.

No other new accounting pronouncement issued or effective during the fiscal year has had, or is expected to have, a material impact on the Company's condensed consolidated financial statements.

[TABLE OF CONTENTS](#)

2. Revenue

The following table is a disaggregation of revenue within each reportable segment.

	Three Months Ended December 31,		Three Months Ended March 31,		Six Months Ended March 31,	
	2023	2022	2024	2023	2024	2023
<i>(In thousands)</i>						
Medical Device						
Product sales	\$ 11,950	\$ 8,380	\$ 11,100	\$ 7,914	\$ 23,050	\$ 16,294
Royalties & license fees – performance coatings	8,208	7,469	10,323	8,098	18,531	15,567
License fees – SurVeil DCB	971	1,296	1,088	1,331	2,059	2,627
Research, development and other	2,416	1,873	2,315	2,364	4,731	4,237
Medical Device Revenue	23,545	19,018	24,826	19,707	48,371	38,725

In Vitro Diagnostics

Product sales	6,877	5,854	6,999	7,436	13,876	13,290
Research, development and other	130	61	133	55	263	116
In Vitro Diagnostics Revenue	7,007	5,915	7,132	7,491	14,139	13,406
Total Revenue	\$ 30,552	\$ 24,933	\$ 31,958	\$ 27,198	\$ 62,510	\$ 52,131

Contract assets totaled \$9.2 million and \$7.8 million as of December 31, 2023 and March 31, 2024 and September 30, 2023, respectively, on the condensed consolidated balance sheets. Fluctuations in the balance of contract assets result primarily from (i) fluctuations in the sales volume of performance coating royalties and license fees earned, but not collected, at each balance sheet date due to payment timing and contractual changes in the normal course of business; and (ii) starting in fiscal 2024, sales-based profit-sharing earned, but not collected, related to a collaborative arrangement (Note 3).

Deferred revenue totaled \$4.7 million and \$6.8 million as of March 31, 2024 and September 30, 2023, respectively, on the condensed consolidated balance sheets and was primarily related to a collaborative arrangement (Note 3). For the six months ended March 31, 2024 and 2023, the total amount of revenue recognized that was included in the respective beginning of fiscal year balances of deferred revenue on the condensed consolidated balance sheets totaled \$2.2 million and \$2.6 million, respectively.

3. Collaborative Arrangement

On February 26, 2018, the Company entered into an agreement with Abbott Vascular, Inc. ("Abbott") with respect to one of the device products in our Medical Device reportable segment, the SurVeil™ drug-coated balloon ("DCB") for treatment of the superficial femoral artery (the "Abbott Agreement"). In June 2023, the SurVeil DCB received U.S. Food and Drug Administration ("FDA") premarket approval ("PMA") and may now be marketed and sold in the U.S. by Abbott.

SurVeil DCB License Fees

Under the Abbott Agreement, Surmodics is responsible for conducting all necessary clinical trials, including completion of the ongoing, five-year TRANSCEND pivotal clinical trial of the SurVeil DCB. The Company has received payments totaling \$87.8 million for achievement of clinical and regulatory milestones under the Abbott Agreement, which consisted of the following: (i) \$25 million upfront fee in fiscal 2018, (ii) \$10 million milestone payment in fiscal 2019, (iii) \$10.8 million milestone payment in fiscal 2020, (iv) \$15 million milestone payment in fiscal 2021, and (v) \$27 million milestone payment in the third quarter of fiscal 2023 upon receipt of PMA for the SurVeil DCB from the FDA. There are no remaining contingent or other milestone payments under the Abbott Agreement.

License fee revenue on milestone payments received under the Abbott Agreement is recognized using the cost-to-cost method based on total costs incurred to date relative to total expected costs for the TRANSCEND pivotal clinical trial, which is expected to be completed in fiscal 2025. See Note 2 Revenue for SurVeil DCB license fee revenue recognized in our Medical Device reportable segment.

As of December 31, 2023 and September 30, 2023 and March 31, 2024, deferred revenue on the condensed consolidated balance sheets totaled included \$5.7 million from upfront and \$6.8 million, respectively, which was primarily related to milestone payments received under the Abbott Agreement. The \$5.7 million in deferred revenue as of December 31, 2023, which represents This represented the Company's remaining performance obligations that are unsatisfied for executed contracts with an original duration of one year or more, and is expected to be recognized as revenue over approximately the next two years one year through fiscal 2025 as services, principally the TRANSCEND clinical trial, are completed.

The amount of revenue recognized that was included in the respective beginning of fiscal year balances of deferred revenue on the condensed consolidated balance sheets totaled \$1.0 million and \$1.3 million for the three months ended December 31, 2023 and 2022, respectively.

TABLE OF CONTENTS

SurVeil DCB Product Sales

Under the Abbott Agreement, we supply commercial units of the *SurVeil* DCB to Abbott, and Abbott has exclusive worldwide distribution rights. During the **three months ended December 31, 2023, first quarter of fiscal 2024**, we commenced shipment of commercial units of the *SurVeil* DCB to Abbott. We recognize revenue from the sale of commercial units of the *SurVeil* DCB to Abbott at the time of shipment in product sales on the condensed consolidated statements of operations. The amount of *SurVeil* DCB product sales revenue recognized includes (i) the contractual transfer price per unit and (ii) an estimate of Surmodics' share of net profits resulting from product sales by Abbott to third parties pursuant to the Abbott Agreement ("estimated *SurVeil* DCB profit-sharing"). On a quarterly basis, Abbott (i) reports to us its third-party sales of the *SurVeil* DCB the quarter after those sales occur, which may occur within two years following shipment based on the product's current shelf life; and (ii) reports to us and pays the actual amount of profit-sharing. Estimated *SurVeil* DCB profit-sharing represents variable consideration and is recorded in contract assets on the condensed consolidated balance sheets. We estimate variable consideration as the most-likely amount to which we expect to be entitled, and we include estimated amounts in the transaction price to the extent it is probable that a significant reversal of cumulative revenue will not occur when the uncertainty associated with the variable consideration is resolved. Significant judgment is required in estimating the amount of variable consideration to recognize when assessing factors outside of Surmodics' influence, such as limited availability of third-party information, expected duration of time until resolution, and limited relevant past experience.

4. Fair Value Measurements

Assets and liabilities measured at fair value on a recurring basis by level of the fair value hierarchy were as follows:

	December 31, 2023				March 31, 2024			
	Significant				Significant			
	Quoted Prices in Active Markets for	Other	Significant		Quoted Prices in Active Markets	Other	Significant	
	Identical Instruments	Observable	Unobservable	Total Fair	for Identical Instruments	Observable	Unobservable	Total Fair
(In thousands)	(Level 1)	(Level 2)	(Level 3)	Value	(Level 1)	(Level 2)	(Level 3)	Value
Assets								
Cash equivalents								
(1)	\$ —	\$ 19,940	\$ —	\$ 19,940	\$ —	\$ 24,297	\$ —	\$ 24,297
Available-for-sale securities (1)	—	11,819	—	11,819	—	7,909	—	7,909
Total assets	\$ —	\$ 31,759	\$ —	\$ 31,759	\$ —	\$ 32,206	\$ —	\$ 32,206
Liabilities								
Interest rate swap								
(2)	—	499	—	499	—	135	—	135
Total liabilities	\$ —	\$ 499	\$ —	\$ 499	\$ —	\$ 135	\$ —	\$ 135

(In thousands)	September 30, 2023					September 30, 2023						
	Quoted Prices				Total Fair Value	Quoted Prices						
	in	Significant				in	Significant					
	Active Markets	Other	Significant			Active Markets	Significant Other	Significant				
	for Identical	Observable	Unobservable			for Identical	Observable	Unobservable				
	Instruments	Inputs	Inputs			Instruments	Inputs	Inputs				
(Level 1)	(Level 2)	(Level 3)		(Level 1)	(Level 2)	(Level 3)		(Level 1)	(Level 2)	(Level 3)		
Assets												
Cash equivalents (1)	\$	—	\$	36,255	\$	—	\$	36,255	\$	—	\$	36,255
Available-for-sale securities (1)		—		3,933		—		3,933		—		3,933
Interest rate swap (2)		—		183		—		183		—		183

Total assets	\$	—	\$	40,371	\$	—	\$	36,255	\$	—	\$	40,371	\$	—	\$	40,371
--------------	----	---	----	--------	----	---	----	--------	----	---	----	--------	----	---	----	--------

- (1) Fair value of cash equivalents (money market funds) and available-for-sale securities (commercial paper and corporate bond securities) was based on quoted vendor prices and broker pricing where all significant inputs are observable.
- (2) Fair value of interest rate swap is based on forward-looking, one-month term secured overnight financing rate ("Term SOFR") spot rates and interest rate curve (Note 7).

10

[TABLE OF CONTENTS](#)

5. Supplemental Balance Sheet Information

Investments — Available-for-sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities were as follows:

(In thousands)	December 31, 2023				March 31, 2024			
	Amortized	Unrealized	Unrealized	Fair	Amortized	Unrealized	Unrealized	Fair
	Cost	Gains	Losses	Value	Cost	Gains	Losses	Value
Commercial paper and corporate bonds	\$ 11,829	\$ —	\$ (10)	\$ 11,819	\$ 7,914	\$ —	\$ (5)	\$ 7,909
Available-for-sale securities	\$ 11,829	\$ —	\$ (10)	\$ 11,819	\$ 7,914	\$ —	\$ (5)	\$ 7,909

(In thousands)	September 30, 2023			
	Amortized	Unrealized	Unrealized	Fair
	Cost	Gains	Losses	Value
Commercial paper and corporate bonds	\$ 3,936	\$ —	\$ (3)	\$ 3,933
Available-for-sale securities	\$ 3,936	\$ —	\$ (3)	\$ 3,933

Inventories

Inventories consisted of the following components:

(In thousands)	December 31,	September 30,	March 31,	September 30,
	2023	2023	2024	2023
Raw materials	\$ 9,091	\$ 8,063	\$ 9,230	\$ 8,063
Work-in process	2,067	2,607	2,508	2,607
Finished products	3,280	4,169	3,667	4,169
Total	\$ 14,438	\$ 14,839		
Inventories	\$ 15,405	\$ 14,839		

Prepays and Other Assets, Current

Prepays and other current assets consisted of the following:

(In thousands)	December 31,	September 30,	March 31,	September 30,
	2023	2023	2024	2023
Prepaid expenses	\$ 3,635	\$ 2,600	\$ 3,557	\$ 2,600
Irish research and development credits receivable	662	1,322	647	1,322
CARES Act employee retention credit receivable (1)	3,441	3,441	—	3,441
Prepays and other	\$ 7,738	\$ 7,363	\$ 4,204	\$ 7,363

- (1) **Receivable** As of September 30, 2023, receivable consisted of anticipated reimbursement of personnel expenses, which were incurred in fiscal periods prior to 2021 and fiscal 2022 2020, as a the result of our eligibility for the employee retention credit under the provisions of the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act"). During the second quarter of fiscal 2024, we received payment for this receivable.

11

[TABLE OF CONTENTS](#)

Intangible Assets

Intangible assets consisted of the following:

(Dollars in thousands)	December 31, 2023				March 31, 2024			
	Weighted Average Original Life (Years)	Gross Carrying Amount	Accumulated Amortization	Net	Weighted Average Original Life (Years)	Gross Carrying Amount	Accumulated Amortization	Net
Definite-lived intangible assets:								
Customer lists and relationships	9.3	\$ 11,742	\$ (10,059)	\$ 1,683	9.3	\$ 11,487	\$ (10,060)	\$ 1,427
Developed technology	11.9	35,116	(12,044)	23,072	11.9	34,489	(12,548)	21,941
Patents and other	14.9	2,338	(1,460)	878	14.9	2,338	(1,502)	836
Total definite-lived intangible assets		49,196	(23,563)	25,633		48,314	(24,110)	24,204
Unamortized intangible assets:								
Trademarks and trade names		580	—	580		580	—	580
Total intangible assets		\$ 49,776	\$ (23,563)	\$ 26,213		\$ 48,894	\$ (24,110)	\$ 24,784

(Dollars in thousands)	September 30, 2023			
	Weighted Average Original Life (Years)	Gross Carrying Amount	Accumulated Amortization	Net
Definite-lived intangible assets:				
Customer lists and relationships	9.3	\$ 11,260	\$ (9,435)	\$ 1,825
Developed technology	11.9	33,929	(11,048)	22,881

Patents and other	14.9	2,338	(1,418)	920
Total definite-lived intangible assets		47,527	(21,901)	25,626
Unamortized intangible assets:				
Trademarks and trade names		580	—	580
Total intangible assets		\$ 48,107	\$ (21,901)	\$ 26,206

Intangible asset amortization expense was \$0.9 million and \$1.0 million for each of the three months ended December 31, 2023, March 31, 2024 and 2022, respectively, 2023 and \$1.9 million for each of the six months ended March 31, 2024 and 2023. Based on the intangible assets in service as of December 31, 2023, March 31, 2024, estimated amortization expense for future fiscal years was as follows:

<i>(In thousands)</i>				
Remainder of 2024	\$	2,866	\$	1,876
2025		3,786		3,717
2026		2,877		2,826
2027		2,624		2,577
2028		2,613		2,566
2029		2,613		2,566
Thereafter		8,254		8,076
Definite-lived intangible assets	\$	25,633	\$	24,204

Future amortization amounts presented above are estimates. Actual future amortization expense may be different as a result of future acquisitions, impairments, changes in amortization periods, foreign currency translation rates, or other factors.

Goodwill

Changes in the carrying amount of goodwill by segment were as follows:

<i>(In thousands)</i>	In Vitro	Medical	Total	In Vitro	Medical	Total
	Diagnostics	Device		Diagnostics	Device	
Goodwill as of September 30, 2023	\$ 8,010	\$ 34,936	\$ 42,946	\$ 8,010	\$ 34,936	\$ 42,946
Currency translation adjustment	—	1,337	1,337	—	630	630
Goodwill as of December 31, 2023	\$ 8,010	\$ 36,273	\$ 44,283			
Goodwill as of March 31, 2024	\$ 8,010	\$ 35,566	\$ 43,576			

[TABLE OF CONTENTS](#)

Other Assets, Noncurrent

Other noncurrent assets consisted of the following:

December 31,	September 30,	March 31,	September 30,
--------------	---------------	-----------	---------------

(In thousands)

	2023	2023	2024	2023
Operating lease right-of-use assets	\$ 3,649	\$ 2,987	\$ 3,435	\$ 2,987
Other	724	877	1,029	877
Other assets	\$ 4,373	\$ 3,864	\$ 4,464	\$ 3,864

Accrued Other Liabilities

Accrued other liabilities consisted of the following:

	December 31, 2023	September 30, 2023	March 31, 2024	September 30, 2023
(In thousands)				
Accrued professional fees	\$ 200	\$ 178	\$ 430	\$ 178
Accrued clinical study expense	405	1,056	579	1,056
Accrued purchases	1,275	1,142	811	1,142
Deferred consideration (1)	2,627	2,661	1,746	2,661
Operating lease liabilities, current portion	997	872	1,001	872
Other	305	535	450	535
Total accrued other liabilities	\$ 5,809	\$ 6,444	\$ 5,017	\$ 6,444

- (1) **Deferred** As of March 31, 2024, deferred consideration consisted of the present value of a guaranteed payment to be made in connection with fiscal 2021 acquisition of Vetex Medical Limited ("Vetex"). As of September 30, 2023, deferred consideration consisted of the present value of guaranteed payments to be made in connection with the fiscal 2021 acquisition of Vetex Medical Limited ("Vetex") acquisition and a fiscal 2022 asset acquisition (Note 11).

Other Long-term Liabilities

Other long-term liabilities consisted of the following:

	December 31, 2023	September 30, 2023	March 31, 2024	September 30, 2023
(In thousands)				
Deferred consideration (1)	\$ 1,637	\$ 1,629	\$ 1,645	\$ 1,629
Unrecognized tax benefits (2)	3,301	3,332	3,308	3,332
Operating lease liabilities, less current portion	3,436	2,974	3,180	2,974
Other	156	125	188	125
Other long-term liabilities	\$ 8,530	\$ 8,060	\$ 8,321	\$ 8,060

- (1) Deferred consideration consisted of the present value of a guaranteed payments payment to be made in connection with the fiscal 2021 Vetex acquisition (Note 11).
- (2) Balance of unrecognized tax benefits includes accrued interest and penalties, if applicable (Note 10).

6. Debt

Debt consisted of the following:

	December 31, 2023	September 30, 2023	March 31, 2024	September 30, 2023
(In thousands)				
Revolving Credit Facility, Term SOFR + 3.00%, maturing October 1, 2027	\$ 5,000	\$ 5,000	\$ 5,000	\$ 5,000
Tranche 1 Term Loans, Term SOFR +5.75%, maturing October 1, 2027	25,000	25,000	25,000	25,000
Long-term debt, gross	30,000	30,000	30,000	30,000
Less: Unamortized debt issuance costs	(557)	(595)	(520)	(595)
Long-term debt, net	\$ 29,443	\$ 29,405	\$ 29,480	\$ 29,405

[TABLE OF CONTENTS](#)

On October 14, 2022, the Company entered into a secured revolving credit facility and secured term loan facilities pursuant to a Credit, Security and Guaranty Agreement (the "MidCap Credit Agreement") with Mid Cap Funding IV Trust, as agent, and MidCap Financial Trust, as term loan servicer and the lenders from time to time party thereto. The MidCap Credit Agreement provides for availability under a secured revolving line of credit of up to \$25.0 million (the "Revolving Credit Facility"). Availability under the Revolving Credit Facility is subject to a borrowing base.

The MidCap Credit Agreement also provides for up to \$75.0 million in term loans (the "Term Loans"), consisting of a \$25.0 million Tranche 1 ("Tranche 1") and a \$50.0 million Tranche 2 ("Tranche 2"), which may be drawn in increments of at least \$10.0 million. In addition, after the closing and prior to December 31, 2024, the Term Loan lenders may, in their sole discretion, fund an additional tranche of Term Loans of up to \$25.0 million upon the written request of the Company. Upon closing, the Company borrowed \$25.0 million of Tranche 1, borrowed \$5.0 million on the Revolving Credit Facility, and used approximately \$10.0 million of the proceeds to repay borrowings under the revolving credit facility with Bridgewater Bank. The Company intends to use the remaining proceeds to fund working capital needs and for other general corporate purposes, as permitted under the MidCap Credit Agreement. Until December 31, 2024, the Company will be eligible to borrow Tranche 2 at the Company's option upon meeting certain conditions set forth in the MidCap Credit Agreement, including having no less than \$60.0 million of rolling-four-quarter core net revenue as of the end of the prior fiscal quarter. Core net revenue is defined in the MidCap Credit Agreement as the sum of revenue from our In Vitro Diagnostics segment and revenues from performance coating technologies in our Medical Device segment.

Pursuant to the MidCap Credit Agreement, the Company provided a first priority security interest in all existing and future acquired assets, including intellectual property and real estate, owned by the Company. The MidCap Credit Agreement contains certain covenants that limit the Company's ability to engage in certain transactions. Subject to certain limited exceptions, these covenants limit the Company's ability to, among other things:

- create, incur, assume or permit to exist any additional indebtedness, or create, incur, allow or permit to exist any additional liens;
- enter into any amendment or other modification of certain agreements;
- effect certain changes in the Company's business, fiscal year, management, entity name or business locations;
- liquidate or dissolve, merge with or into, or consolidate with, any other company;
- pay cash dividends on, make any other distributions in respect of, or redeem, retire or repurchase, any shares of the Company's capital stock;
- make certain investments, other than limited permitted acquisitions; and
- enter into transactions with the Company's affiliates.

The MidCap Credit Agreement also contains customary indemnification obligations and customary events of default, including, among other things, (i) non-payment, (ii) breach of warranty, (iii) non-performance of covenants and obligations, (iv) default on other indebtedness, (v) judgments, (vi) change of control, (vii) bankruptcy and insolvency, (viii) impairment of security, (ix) termination of a pension plan, (x) regulatory matters, and (xi) material adverse effect.

In addition, the Company must maintain minimum core net revenue levels tested quarterly to the extent that Term Loans advanced under the MidCap Credit Agreement exceed \$25.0 million. In the event of default under the MidCap Credit Agreement, the Company would be required to pay interest on principal and all other due and unpaid obligations at the current rate in effect plus 2%.

Borrowings under the MidCap Credit Agreement bear interest at the forward-looking, one-month secured overnight financing rate ("Term SOFR") as published by CME Group Benchmark Administration Limited plus 0.10% ("Adjusted Term SOFR"). The Revolving Credit Facility bears interest at an annual rate equal to 3.00% plus the greater of Adjusted Term SOFR or 1.50%, and the Term Loans bear interest at an annual rate equal to 5.75% plus the greater of Adjusted Term SOFR or 1.50%. The Company is required to make monthly interest payments on the Revolving Credit Facility with the entire principal payment due at maturity. The Company is required to make 48 monthly interest payments on the Term Loans beginning on November 1, 2022 (the "Interest-Only Period"). If the

Company is in covenant compliance at the end of the Interest-Only Period, the Company will have the option to extend the Interest-Only Period through maturity with the entire principal payment due at maturity. If the Company is not in covenant compliance at the end of the Interest-Only Period, the Company is required to make 12 months of straight-line amortization payments with the entire principal amount due at maturity.

[TABLE OF CONTENTS](#)

Subject to certain limitations, the Term Loans have a prepayment fee for payments made prior to the maturity date equal to 2.0% of the prepaid principal amount for the second year following the closing date and 1.0% of the prepaid principal amount for the third year following the closing date and thereafter. In addition, if the Revolving Credit Facility is terminated in whole or in part prior to the maturity date, the Company must pay a prepayment fee equal to 2.0% of the terminated commitment amount for the second year following the closing date of the MidCap Credit Agreement and 1.0% of the terminated commitment amount for the third year following the closing date and thereafter. The Company is also required to pay a full exit fee at the time of maturity or full prepayment event equal to 2.5% of the aggregate principal amount of the Term Loans made pursuant to the MidCap Credit Agreement and a partial exit fee at the time of any partial prepayment event equal to 2.5% of the amount prepaid. This exit fee is accreted over the remaining term of the Term Loans. The Company also is obligated to pay customary origination fees at the time of each funding of the Term Loans and a customary annual administrative fee based on the amount borrowed under the Term Loan, due on an annual basis. The customary fees on the Revolving Credit Facility include (i) an origination fee based on the commitment amount, which was paid on the closing date, (ii) an annual collateral management fee of 0.50% per annum based on the outstanding balance of the Revolving Credit Facility, payable monthly in arrears and (iii) an unused line fee of 0.50% per annum based on the average unused portion of the Revolving Credit Facility, payable monthly in arrears. The Company must also maintain a minimum balance of no less than 20% of availability under the Revolving Credit Facility or a minimum balance fee applies of 0.50% per annum. Expenses recognized for fees for the Revolving Credit Facility and Term Loans are reported in interest expense, net on the condensed consolidated statements of operations.

7. Derivative Financial Instruments

As of **December 31, 2023** **March 31, 2024** and September 30, 2023, derivative financial instruments on the condensed consolidated balance sheets consisted of a fixed-to-variable interest rate swap to mitigate exposure to interest rate increases related to our Term Loans ("interest rate swap"). The interest rate swap has been designated as a cash flow hedge. See Note 6 Debt for further information on our financing arrangements. The net fair value of designated hedge derivatives subject to master netting arrangements reported on the condensed consolidated balance sheets was as follows:

(In thousands)	Asset (Liability)						Asset (Liability)					
	Gross	Gross	Net	Cash	Net	Balance Sheet	Gross	Gross	Net	Cash	Net	Balance
	Recognized	Offset	Amount	Collateral	Amount		Recognized	Offset	Amount	Collateral	Amount	Sheet
	Amount	Amount	Presented	Receivable	Reported	Location	Amount	Amount	Presented	Receivable	Reported	Location
December 31, 2023												
March 31, 2024												
Interest rate swap	\$ (499)	\$ —	\$ (499)	\$ 520	\$ 21	Other assets, noncurrent	\$ (135)	\$ —	\$ (135)	\$ 527	\$ 392	Other assets, noncurrent
September 30, 2023												

Interest rate swap	\$	183	\$	—	\$	183	\$	—	\$	183	Other assets, noncurrent	\$	183	\$	—	\$	183	Other assets, noncurrent
--------------------	----	-----	----	---	----	-----	----	---	----	-----	--------------------------	----	-----	----	---	----	-----	--------------------------

The pretax amounts recognized in accumulated other comprehensive loss ("AOCL") for designated hedge derivative instruments were as follows:

(In thousands)	Three Months Ended December 31,		Three Months Ended March 31,		Six Months Ended March 31,	
	2023	2022	2024	2023	2024	2023
Beginning unrealized net gain in AOCL	\$ 183	\$ —				
Net loss recognized in other comprehensive income (loss)	(620)	(444)				
Beginning unrealized net (loss) gain in AOCL	\$ (499)	\$ —	\$ 183	\$ —		
Net gain (loss) recognized in other comprehensive (loss) income	426	(304)	(194)	(748)		
Net (gain) loss reclassified into interest expense	(62)	31	(62)	(11)	(124)	20
Ending unrealized loss in AOCL	\$ (499)	\$ (413)	\$ (135)	\$ (315)	\$ (135)	\$ (728)

15

[TABLE OF CONTENTS](#)

8. Stock-based Compensation Plans

The Company has stock-based compensation plans approved by its shareholders under which it grants stock options, restricted stock awards, restricted stock units and deferred stock units to officers, directors and key employees. Stock-based compensation expense was reported as follows in the condensed consolidated statements of operations:

(In thousands)	Three Months Ended December 31,	
	2023	2022
Product costs	\$ 72	\$ 67
Research and development	370	374
Selling, general and administrative	1,526	1,524
Total	\$ 1,968	\$ 1,965

15

[TABLE OF CONTENTS](#)

(In thousands)	Three Months Ended March 31,		Six Months Ended March 31,	
	2024	2023	2024	2023
Product costs	\$ 70	\$ 72	\$ 142	\$ 139
Research and development	389	329	759	703
Selling, general and administrative	1,667	1,381	3,193	2,905
Total	\$ 2,126	\$ 1,782	\$ 4,094	\$ 3,747

As of **December 31, 2023** **March 31, 2024**, unrecognized compensation costs related to non-vested awards totaled approximately \$**16.0** **14.9** million, which is expected to be recognized over a weighted average period of approximately **2.7** **2.4** years.

Stock Option Awards

The Company awards stock options to officers, directors and key employees and uses the Black-Scholes option pricing model to determine the fair value of stock options as of the date of each grant. Stock option grant activity was as follows:

	Three Months Ended December 31,		Six Months Ended March 31,	
	2023	2022	2024	2023
Stock option grant activity:				
Stock options granted	250,000	269,000	281,000	293,000
Weighted average grant date fair value	\$ 15.82	\$ 15.53	\$ 15.70	\$ 15.27
Weighted average exercise price	\$ 33.64	\$ 35.97	\$ 33.40	\$ 35.40

Restricted Stock Awards

During the **three six** months ended **December 31, 2023** **March 31, 2024** and **2022**, **2023**, the Company awarded **98,000** **102,000** and 99,000 restricted stock shares, respectively, to certain key employees and officers with a weighted average grant date fair value per share of \$**33.64** **33.53** and \$36.05, respectively. Restricted Stock is valued based on the market value of the shares as of the date of grant.

Restricted Stock Unit Awards

During each of the **three six** months ended **December 31, 2023** **March 31, 2024** and **2022**, **2023**, the Company awarded **5,000** **14,000** and **16,000** restricted stock units ("RSUs"), respectively, to directors and to key employees in foreign jurisdictions with a weighted average grant date fair value per unit of \$**33.64** **32.49** and \$**36.13** **31.72**, respectively. RSUs are valued based on the market value of the shares as of the date of grant.

Employee Stock Purchase Plan

Our U.S. employees are eligible to participate in the amended 1999 Employee Stock Purchase Plan ("ESPP") approved by our shareholders. During the **three six** months ended **December 31, 2023** **March 31, 2024** and **2022**, **2023**, **no** **16,000** and **23,000** shares were issued under the **ESPP**. **ESPP**, respectively.

9. Net **Loss** **Income (Loss)** Per Share Data

Basic net income (loss) per common share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of common and common equivalent shares outstanding during the period. The Company's potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards and restricted stock units.

16

[TABLE OF CONTENTS](#)

The calculation of diluted loss per share excluded 0.1 million **or less** in weighted-average shares for each of the three months ended **December 31, 2023** **March 31, 2024** and **2022**, **2023** and 0.1 million **or less** in weighted average shares for each of the six months ended **March 31, 2024** and **2023**, as their effect was anti-dilutive. Basic and diluted weighted average shares outstanding were as follows:

	Three Months Ended		Three Months Ended		Six Months Ended	
	December 31,		March 31,		March 31,	
	2023	2022	2024	2023	2024	2023
(In thousands)						

Basic weighted average shares outstanding	14,102	13,983	14,152	14,030	14,127	14,010
Dilutive effect of outstanding stock options, non-vested restricted stock, and non-vested restricted stock units	—	—	30	—	—	—
Diluted weighted average shares outstanding	14,102	13,983	14,182	14,030	14,127	14,010

16

TABLE OF CONTENTS

10. Income Taxes

For interim income tax reporting, the Company estimates its full-year effective tax rate and applies it to fiscal year-to-date pretax income (loss), excluding unusual or infrequently occurring discrete items. Tax jurisdictions with losses for which tax benefits cannot be realized are excluded. The Company reported an income tax expense benefit of \$(0.1) million and income tax expense of \$(0.4) million for the three months ended March 31, 2024 and 2023, respectively, and income tax benefit of \$0.0 million and income tax expense of \$(0.2) million for the three six months ended December 31, 2023 March 31, 2024 and 2022, 2023, respectively.

- Beginning in our fiscal 2023, certain research and development ("R&D") costs are required to be capitalized and amortized over a five-year period under the Cuts and Jobs Act enacted in December 2017. This change impacts the expected U.S. federal and state income tax expense and cash taxes paid and to be paid for our fiscal 2024 and 2023.
- Since September 30, 2022, we have maintained a full valuation allowance against U.S. net deferred tax assets. As a result, we are no longer recording a benefit associated with U.S. pretax losses and incremental deferred tax assets.
- Recurring items cause our effective tax rate to differ from the U.S. federal statutory rate of 21%, including foreign-derived intangible income ("FDII") deductions in the U.S., U.S. federal and Irish R&D credits, Irish and U.S. state tax rates, and excess tax benefits associated with stock-based compensation.

A valuation allowance is required to be recognized against deferred tax assets if, based on the available evidence, it is more likely than not (defined as a likelihood of more than 50%) that all or a portion of such assets will not be realized. We apply judgment to consider the relative impact of negative and positive evidence, and the weight given to negative and positive evidence is commensurate with the extent to which such evidence can be objectively verified. Objective historical evidence, such as cumulative three-year pre-tax income (losses) losses adjusted for permanent adjustments, is given greater weight than subjective positive evidence, such as forecasts of future earnings. The more objective negative evidence that exists limits our ability to consider other, potentially positive, subjective evidence, such as our future earnings projections. Based on our evaluation of all available positive and negative evidence, and by placing greater weight on the objectively verifiable evidence, we determined, as of December 31, 2023 March 31, 2024 and September 30, 2023, that it is more likely than not that our net U.S. deferred tax assets will not be realized. Due to significant estimates used to establish the valuation allowance and the potential for changes in facts and circumstances, it is reasonably possible that we will be required to record additional adjustments to the valuation allowance in future reporting periods that could have a material effect on our results of operations.

Discrete tax benefits related to stock-based compensation awards vested, expired, canceled and exercised was \$0.1 million or less for each of the three months ended December 31, 2023 and 2022, 2022 and \$0.1 million or less for each of the six months ended March 31, 2024 and 2023. The total amount of unrecognized tax benefits, excluding interest and penalties that, if recognized, would affect the effective tax rate was \$3.7 3.6 million and \$3.1 million as of December 31, 2023 March 31, 2024 and September 30, 2023, respectively. Interest and penalties related to unrecognized tax benefits are recorded in the income tax benefit (expense) benefit.

17

TABLE OF CONTENTS

The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions, as well as several non-U.S. jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service commenced an examination of the Company's fiscal 2019 U.S. federal tax return in fiscal 2022; the examination has not been completed. U.S. federal income tax returns for years prior to fiscal 2019 are no longer subject to examination by federal tax authorities. For tax returns for U.S. state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2013. For tax returns for non-U.S. jurisdictions, the Company is no longer subject to income tax examination for years prior to 2019. There were no undistributed earnings in foreign subsidiaries as of **December 31, 2023**, **March 31, 2024** and September 30, 2023.

11. Commitments and Contingencies

Asset Acquisitions. Acquisition. In fiscal 2018, the Company acquired certain intellectual property assets of Embolitech, LLC (the "Embolitech Transaction"). As part of the Embolitech Transaction, the Company paid the sellers \$5.0 million in fiscal 2018, \$1.0 million in fiscal 2020, \$1.0 million in fiscal 2021, \$0.5 million in fiscal 2022, and \$1.0 million in fiscal 2023. The Company is obligated to pay an additional installment of 2023, and \$0.9 million in fiscal 2024, which may be accelerated upon the occurrence of certain sales and regulatory milestones. An additional \$1.0 million payment is contingent upon the achievement of a certain regulatory milestone within a contingency period ending in 2033.

17

TABLE OF CONTENTS

Vetex Acquisition. In fiscal 2021, Surmodics acquired all of the outstanding shares of Vetex with an upfront cash payment of \$39.9 million. The Company is obligated to pay two installments, each in the amount of \$1.8 million, in the fourth quarter of fiscal 2024 and fiscal 2027. These payments may be accelerated upon the occurrence of certain product development and regulatory milestones. An additional \$3.5 million in payments is contingent upon the achievement of certain product development and regulatory milestones within a contingency period ending in fiscal 2027.

12. Segment Information

Segment revenue, operating loss, income (loss), and depreciation and amortization were as follows:

(In thousands)	Three Months Ended December 31,		Three Months Ended March 31,		Six Months Ended March 31,	
	2023	2022	2024	2023	2024	2023
Revenue:						
Medical Device	\$ 23,545	\$ 19,018	\$ 24,826	\$ 19,707	\$ 48,371	\$ 38,725
In Vitro Diagnostics	7,007	5,915	7,132	7,491	14,139	13,406
Total revenue	\$ 30,552	\$ 24,933	\$ 31,958	\$ 27,198	\$ 62,510	\$ 52,131
Operating loss:						
Operating income (loss):						
Medical Device	\$ (224)	\$ (7,235)	\$ 302	\$ (7,059)	\$ 78	\$ (14,294)
In Vitro Diagnostics	3,124	2,948	3,356	3,636	6,480	6,584
Total segment operating income (loss)	2,900	(4,287)	3,658	(3,423)	6,558	(7,710)
Corporate	(3,222)	(2,942)	(2,999)	(3,160)	(6,221)	(6,102)
Total operating loss	\$ (322)	\$ (7,229)				

Total operating income (loss)	\$ 659	\$ (6,583)	\$ 337	\$ (13,812)		
Depreciation and amortization:						
Medical Device	\$ 2,054	\$ 1,953	\$ 1,916	\$ 1,933	\$ 3,970	\$ 3,886
In Vitro Diagnostics	97	77	96	75	193	152
Corporate	182	92	84	84	266	176
Total depreciation and amortization	\$ 2,333	\$ 2,122	\$ 2,096	\$ 2,092	\$ 4,429	\$ 4,214

The Corporate category includes expenses that are not fully allocated to the Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors. Corporate may also include expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to the reportable segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

[TABLE OF CONTENTS](#)

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information management believes is useful in understanding the operating results, cash flows and financial condition of Surmodics. The discussion should be read in conjunction with both the unaudited condensed consolidated financial statements and related notes included in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes and Management's Discussion and Analysis of Financial Condition and Results of Operations, each included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023. This discussion contains various "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statement entitled "Forward-Looking Statements" located at the end of this Item 2.

Overview

Surmodics, Inc. (referred to as "Surmodics," the "Company," "we," "us," "our" and other like terms) is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic ("IVD") immunoassay tests and microarrays. Surmodics develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company's expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development and manufacturing capabilities. The Company's mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota.

Vascular Intervention Medical Device Platforms

Within our Medical Device segment, we develop and manufacture our own proprietary vascular intervention medical device products, which leverage our expertise in performance coating technologies, product design and engineering capabilities. We believe our strategy of developing our own medical device products has increased, and will continue to increase, our relevance in the medical device industry. This strategy is key to our future growth and profitability, providing us with the opportunity to capture more revenue and operating margin with vascular intervention device products than we would by licensing our device-enabling technologies.

Highlighted below are select medical device products within our development pipeline that are our focus for development commercialization and commercialization development efforts. For our drug-coated balloon ("DCB") platform, we are commercializing commercialized our SurVeil™ DCB through a distribution arrangement with Abbott Vascular, Inc. ("Abbott"). For both our thrombectomy and radial access platforms, we are pursuing commercialization via a direct sales strategy leveraging a small team of experienced sales professionals and clinical specialists. Beginning in fiscal 2022, we began to see modest, but meaningful and growing revenue associated with the adoption, utilization and sales of our Pounce™ and Sublime™ platform products.

Drug-coated Balloon Platform

Surmodics' DCBs are designed for vascular interventions to treat peripheral arterial disease ("PAD"), a condition that causes a narrowing of the blood vessels supplying the extremities.

- **SurVeil DCB** is a paclitaxel-coated DCB to treat PAD in the upper leg (superficial femoral artery), which utilizes a proprietary paclitaxel drug-excipient formulation for a durable balloon coating and is manufactured using an innovative process to improve coating uniformity. In June 2023, the SurVeil DCB received U.S. Food and Drug Administration ("FDA") premarket approval ("PMA") and may now be marketed and sold in the U.S. by Abbott under our exclusive worldwide distribution agreement for the product (the "Abbott Agreement"). The SurVeil DCB also has the necessary regulatory approval for commercialization in the European Union ("E.U.").

In the first quarter of fiscal 2024, we completed shipment of Abbott's initial stocking order of commercial units of the SurVeil DCB, resulting in recognition of product sales, which included both (i) the contractual transfer price, and (ii) an estimate of Surmodics' share of net profits resulting from product sales by Abbott to third parties. As of January 2024, the SurVeil DCB is now a commercial product available in the U.S. through Abbott. In the second quarter of fiscal 2024, we continued to manufacture and ship commercial units to Abbott in support of Abbott's commercialization of the product.

- **Sundance™ DCB** is a sirolimus-coated DCB used for the treatment of below-the-knee PAD. We completed six-month patient follow-up visits in the fourth quarter of fiscal 2021 for the SWING first-in-human, 35-patient clinical study of our Sundance DCB. SWING study data at 24 months have demonstrated an excellent safety profile and promising signals of potential performance. We continue to evaluate our strategy for further clinical investment in the Sundance DCB based on the experience we have gained from the PMA application process for the SurVeil DCB.

19

TABLE OF CONTENTS

Pounce Thrombectomy Platform Systems

We have successfully developed, internally and through acquisitions, multiple FDA 510(k)-cleared mechanical thrombectomy devices, which require no capital equipment, for the non-surgical removal of thrombi and emboli (clots) from the peripheral vasculature. In addition to FDA clearance, our Pounce Venous Thrombectomy System has arterial and venous vasculatures, while minimizing the necessary regulatory approval need for commercialization in the E.U. thrombolytics. We believe that the ease of use, intuitive design, and efficient performance of our thrombectomy products systems make these devices viable products attractive first-line treatment options for interventionalists. These devices include:

- **Pounce Arterial Thrombectomy System Platform**, indicated for the peripheral arterial vasculature, is a suite of mechanical thrombectomy systems designed for the capture and non-surgical removal of clots from arteries in thrombi and emboli (clots) without the peripheral vasculature associated with PAD. Commercial sales began in need for capital equipment or aspiration while minimizing the first quarter use of fiscal 2022. thrombolytics. Two different-sized systems are commercially available.

In The original Pounce (mid profile) Thrombectomy System is indicated for use in peripheral arterial vessels 3.5 mm to 6 mm in diameter, such as those found above the third quarter of fiscal 2023, the low-profile (LP) model knee. Commercial sales of the Pounce Arterial Thrombectomy System began in fiscal 2022.

The Pounce LP (Low Profile) Thrombectomy System is indicated for use in peripheral arterial vessels 2 mm to 4 mm in diameter, such as those found below the knee. The Pounce LP Thrombectomy System received FDA 510(k) regulatory clearance which will allow for clot removal in below-the-knee

peripheral arteries (2 mm to 4 mm) the third quarter of fiscal 2023, and we began limited market evaluations of the product in diameter), expanding the addressable market for first quarter of fiscal 2024. In the Pounce platform. Limited third quarter of fiscal 2024, we completed limited market evaluations for the Pounce LP device began in Thrombectomy System, and the first quarter of fiscal 2024, and transition to commercial launch is targeted for fiscal 2024. product was commercially launched.

- Pounce Venous Thrombectomy System** is a mechanical thrombectomy system indicated for the removal mechanical de-clotting and controlled and selective infusion of clots from veins physician-specified fluids, including thrombolytics, in the peripheral vasculature generally associated with vasculature. The Pounce Venous System is designed to remove mixed-morphology, wall-adherent venous thromboembolism ("VTE"). clot in a single session, minimizing the need for thrombolytics and without the need for capital equipment. We conducted limited market evaluations of the Pounce Venous Thrombectomy System in fiscal 2023 and in the first six months of fiscal 2024 to obtain physician feedback across a variety of cases and clinical conditions. Completion In the second quarter of fiscal 2024, we completed limited market evaluations for the PounceVenous Thrombectomy System, and transition to commercial launch are targeted for fiscal 2024. the product was commercially launched.

Sublime Radial Access Platform

We have successfully developed and received FDA 510(k) regulatory clearance for a suite of devices that enable vascular intervention designed to access and treat stenosed (narrowed) arteries from the thigh to the foot via radial (wrist) access. Our Sublime radial access for which commercial platform provides a unique combination of length, profile and deliverability, allowing physicians to access and treat lesions previously inaccessible via radial access. Commercial sales of the Sublime guide sheath and RX PTA dilatation catheter devices began in the first quarter of fiscal 2022. These devices include:

- Sublime guide sheath** to provide provides the conduit for peripheral intervention with an access point at the wrist that enables treatment all the way to the pedal loop of the foot.
- Sublime .014 RX PTA dilatation catheter** for treatment of treats lesions in peripheral arteries below the knee all the way to the patient's foot and around the pedal loop.
- Sublime .018 RX PTA dilatation catheter** for treatment of treats lesions in peripheral arteries above and below the knee.
- Sublime microcatheter**, peripheral microcatheters with multiple configurations (compatible with .014, (.014, .018 and .035 guidewires).035) facilitate guidewire placement for difficult to access to and treat arterial lesions above and below the knee using radial, femoral, or alternate access site approaches. sites. Limited market evaluations of the our Sublime microcathetermicrocatheters began in the third quarter of fiscal 2023 and are expected to continue in fiscal 2024.

For more information regarding our vascular intervention medical devices, see Part I, Item 1 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023.

[TABLE OF CONTENTS](#)

Results of Operations

Three and Six Months Ended December 31, 2023 March 31, 2024 and 2022 2023

Revenue. Revenue in the firstsecond quarter of fiscal 2024 was \$30.6 million \$32.0 million, a \$5.6 million \$4.8 million or 23%18% increase compared to the prior-year quarter. Revenue in the first six months of fiscal 2024 was \$62.5 million, a \$10.4 million or 20% increase compared to the same prior-year period. The following is a summary of revenue streams within each reportable segment.

(Dollars in thousands)	Three Months Ended December 31,			Three Months Ended March 31,			Six Months Ended March 31,		
	2023	2022	Increase/(Decrease)	2024	2023	Increase/(Decrease)	2024	2023	Increase/(Decrease)

Medical Device												
Product sales	\$ 11,950	\$ 8,380	\$ 3,570	43 %	\$ 11,100	\$ 7,914	\$ 3,186	40 %	\$ 23,050	\$ 16,294	\$ 6,756	41 %
Royalties & license fees – performance coatings	8,208	7,469	739	10 %	10,323	8,098	2,225	27 %	18,531	15,567	2,964	19 %
License fees – SurVeil DCB	971	1,296	(325)	(25) %	1,088	1,331	(243)	(18) %	2,059	2,627	(568)	(22) %
R&D and other	2,416	1,873	543	29 %	2,315	2,364	(49)	(2) %	4,731	4,237	494	12 %
Medical Device Revenue	23,545	19,018	4,527	24 %	24,826	19,707	5,119	26 %	48,371	38,725	9,646	25 %
In Vitro Diagnostics												
Product sales	6,877	5,854	1,023	17 %	6,999	7,436	(437)	(6) %	13,876	13,290	586	4 %
R&D and other	130	61	69	113 %	133	55	78	142 %	263	116	147	127 %
In Vitro Diagnostics Revenue	7,007	5,915	1,092	18 %	7,132	7,491	(359)	(5) %	14,139	13,406	733	5 %
Total Revenue	\$ 30,552	\$ 24,933	\$ 5,619	23 %	\$ 31,958	\$ 27,198	\$ 4,760	18 %	\$ 62,510	\$ 52,131	\$ 10,379	20 %

Medical Device. Revenue in our Medical Device segment was \$23.5 million \$24.8 million in the first second quarter of fiscal 2024, a 24% 26% increase from \$19.0 million \$19.7 million in the prior-year quarter. For the first six months of fiscal 2024, revenue in our Medical Device segment was \$48.4 million, a 25% increase from \$38.7 million in the same prior-year period.

- Medical Device product sales increased 43% 40% to \$12.0 million \$11.1 million in the first second quarter of fiscal 2024, compared to \$8.4 million \$7.9 million in the prior-year quarter. For the first six months of fiscal 2024, Medical Device product sales increased 41% to \$23.1 million, compared to \$16.3 million in the same prior-year period. Product sales growth year-over-year was primarily driven by fulfillment of the initial stocking order and subsequent orders for the SurVeil DCB from Abbott, our exclusive distribution partner for the product, and continued sales growth from the Pounce thrombectomy device platform.
- Performance coating royalties and license fee revenue increased 10% 27% to \$8.2 million \$10.3 million in the first second quarter of fiscal 2024, compared to \$7.5 million \$8.1 million in the prior-year quarter. For the first six months of fiscal 2024, performance coating royalties and license fee revenue increased 19% \$18.5 million, compared to \$15.6 million the same prior-year period. In the second quarter primarily driven by and first six months of fiscal 2024, performance coating royalties and license fee revenue benefited from \$1.4 million in catch-up payments in the normal course of our customers reporting sales-based royalties, customer-reported royalties in excess of estimated royalties, and continued growth from customers utilizing in customer utilization of our Serer hydrophilic coating.
- SurVeil DCB license fee revenue under the Abbott Agreement was \$1.0 million \$1.1 million and \$1.3 million in the second quarter of fiscal 2024 and 2023, respectively, and \$2.1 million and \$2.6 million in the first quarter six months of fiscal 2024 and 2023, respectively. The year-over-year decline in SurVeil DCB license fee revenue was driven by lower TRANSCEND clinical trial costs subsequent to receipt of PMA from the FDA for the SurVeil DCB in the third quarter of fiscal 2023.
- Medical Device research and development (“R&D”) and other revenue increased \$0.5 million to \$2.4 million of \$2.3 million in the first second quarter of fiscal 2024 was flat compared to \$1.9 million in the prior-year quarter. For the first six months of fiscal 2024, Medical Device R&D and other revenue increased \$0.5 million to \$4.7 million, compared to the same prior-year period, driven by increased volume of performance coating services. services and commercial development projects.

In Vitro Diagnostics. Revenue in our In Vitro Diagnostics (“IVD”) segment was \$7.0 million \$7.1 million in the first second quarter of fiscal 2024, an 18% increase a 5% decrease from \$5.9 million \$7.5 million in the prior-year quarter. For the first six months of fiscal 2024, revenue in our IVD segment was \$14.1 million, a 5% increase from \$13.4 million in the same prior-year period.

- IVD product sales increased 17% decreased 6% to \$6.9 million \$7.0 million in the first second quarter of fiscal 2024, compared to \$5.9 million \$7.4 million in prior-year quarter. IVD product sales in the second quarter of fiscal 2024 declined compared to the prior-year quarter, which was the peak revenue quarter during fiscal 2023, primarily driven by lower sales of colorimetric substrate products. For the first six months of fiscal 2024, IVD product sales increased 49% \$13.9 million, compared to \$13.3 million in the same prior-year period, primarily driven by strong customer demand and favorable order timing for distribution antigen and microarray slide/surface products, partly offset by lower sales of colorimetric substrate and protein stabilization products.

TABLE OF CONTENTS

- IVD R&D and other revenue was of \$0.1 million for both in the first second quarter of fiscal 2024 was flat compared to the prior-year quarter. For the first months of fiscal 2024, IVD R&D and 2023, other revenue increased to \$0.3 million, compared to \$0.1 million for the same prior-year period, driven by custo development projects.

21

TABLE OF CONTENTS

Operating Costs and Expenses. Product sales, product costs, product gross profit, product gross margin, and operating costs were as follows:

(Dollars in thousands)	Three Months Ended December 31,				Three Months Ended March 31,				Six Months Ended March 31,			
	2023	2022	Increase/(Decrease)		2024	2023	Increase/(Decrease)		2024	2023	Increase/(Decrease)	
Product sales	\$ 18,827	\$ 14,234	\$ 4,593	32 %	\$ 18,099	\$ 15,350	\$ 2,749	18 %	\$ 36,926	\$ 29,584	\$ 7,342	25 %
Product costs	8,803	5,267	3,536	67 %	7,101	5,738	1,363	24 %	15,904	11,005	4,899	45 %
Product gross profit (1)	10,024	8,967	1,057	12 %	10,998	9,612	1,386	14 %	21,022	18,579	2,443	13 %
% Product gross margin (2)	53.2 %	63.0 %	(9.8) ppt		60.8 %	62.6 %	(1.8) ppt		56.9 %	62.8 %	(5.9) ppt	
R&D expense	8,664	12,743	(4,079)	(32) %	10,229	12,924	(2,695)	(21) %	18,893	25,667	(6,774)	(26) %
% Total revenue	28 %	51 %			32 %	48 %			30 %	49 %		
SG&A expense	12,537	13,236	(699)	(5) %	13,093	12,967	126	1 %	25,630	26,203	(573)	(2) %
% Total revenue	41 %	53 %			41 %	48 %			41 %	50 %		
Acquired intangible asset amortization	870	913	(43)	(5) %	876	867	9	1 %	1,746	1,780	(34)	(2) %
Restructuring expense	—	1,282	(1,282)		—	1,282	(1,282)					
Contingent consideration expense	—	3	(3)		—	3	(3)		—	6	(6)	

(1) Product gross profit is defined as product sales less related product costs.

(2) Product gross margin is defined as product gross profit as a percentage of product sales.

Product **gross profit** *Gross Profit* and **product gross margins**. *Product Gross Margins*. Product gross profit increased **\$1.1 million** **\$1.4 million**, or **12%** **14%**, in the **first** second quarter of fiscal 2024, compared to the prior-year quarter, and increased \$2.4 million, or 13%, in the first six months of fiscal 2024, compared to the same prior-year period. Product gross margins were **53.2%** **60.8%** and **63.0%** **62.6%** in the second quarter of fiscal 2024 and 2023, respectively, and 56.9% and 62.8% in the first **quarter** **six months** of fiscal 2024 and 2023, respectively. The **year-over-year** decrease in product gross **margin in the first quarter of fiscal 2024 margins** was primarily driven by **several factors**.

- **Sales** **increased sales** of vascular intervention medical devices – our *SurVeil* DCB, *Pounce* thrombectomy, and *Sublime* radial access products – **increased** as a proportion of total product sales, **in the first quarter of fiscal 2024, compared to the prior-year period, which had an unfavorable revenue mix impact to as these devices were not at scale, and** product gross **margin. In margins reflected** the first quarter of fiscal 2024 and 2023, product margins for our vascular interventions devices were impacted by the **associated** under-absorption **of fixed costs** and production **inefficiencies, including expiration of inventory, associated with production volumes that were below full scale.**
- **Sales of relatively lower-margin IVD antigen products, which we sell as a distributor, increased year-over-year in the first quarter of fiscal 2024, resulting in unfavorable revenue mix impact to product gross margin.**
- **Product gross margin in the first quarter of fiscal 2024 was unfavorably impacted by fixed overhead cost absorption to a greater degree, relative to the prior-quarter, from a timing-related decrease in production volumes.**

inefficiencies. In fiscal 2024, product gross margins may continue to be adversely impacted by the shift in revenue mix towards sales of vascular intervention medical devices at relatively lower margins.

R&D **expense.** *Expense*. R&D expense declined **32%** **21%**, or **\$4.1 million** **\$2.7 million**, in the **first** second quarter of fiscal 2024, compared to the prior-year quarter. **For the first six months of fiscal 2024, R&D expense declined 26%, or \$6.8 million, compared to the same prior-year period.** R&D expense as a percentage of revenue was **28%** **32%** and **51%** **48%** in the second quarter of fiscal 2024 and 2023, respectively, and 30% and 49% in the first **quarter** **six months** of fiscal 2024 and 2023, respectively. The decrease in R&D expense was primarily driven by lower *SurVeil* DCB R&D expenses due to the transition to commercialization, **lower thrombectomy platform R&D expenses due to the timing of** **certain investments in product development and commercialization of device products,** and the spending reduction plan and workforce reduction implemented in the second quarter of fiscal **2023., 2023.** For full-year fiscal 2024, we expect R&D expense to decrease **between \$5.5 million and \$6.5 million by approximately \$6.0 million to \$7.0 million,** compared to fiscal 2023, primarily related to lower *SurVeil* DCB expenses as the result of transition to commercialization and the workforce reduction implemented in the second quarter of fiscal 2023, partly offset by our continued investment in our *Pounce* thrombectomy and *Sublime* radial access product platforms.

Selling, **general** *General* and **administrative** *Administrative* (“SG&A”) **expense.** *Expense*. SG&A expense **decreased 5%, or \$0.7 million** in the **first** second quarter of fiscal 2024 **was flat** compared to the prior-year quarter. **For the first six months of fiscal 2024, SG&A expense declined 2%, or \$0.6 million, compared to the same prior-year period.** SG&A expense as a percentage of revenue was 41% and **53%** **48%** in the **first** second quarter of fiscal 2024 and 2023, **respectively, and** **41% and 50% in the first six months of fiscal 2024 and 2023, respectively.** **The** **For the first six months of fiscal 2024, the year-over-year** decrease in SG&A expense was primarily related to lower **headcount, largely** **compensation expenses, primarily** as the result of the spending reduction plan and workforce reduction implemented in the second quarter of fiscal 2023. For full-year fiscal 2024, we expect SG&A expense to increase **between by approximately \$1.0 million to \$2.0 million and \$3.0 million,** compared to fiscal 2023, as we continue to advance the commercialization of our *Pounce* thrombectomy and *Sublime* radial access product platforms.

TABLE OF CONTENTS

Acquired **intangible asset amortization.** *Intangible Asset Amortization*. We have previously acquired certain intangible assets through business combinations, which are amortized over periods ranging from seven to 14 years.

22 Restructuring Expense

TABLE OF CONTENTS . In the second quarter of fiscal 2023, we initiated a spending reduction plan intended to preserve capital and more closely align our capital allocation priorities with our strategic objectives, which included a workforce restructuring in our Medical Device segment. As a result, for the three and six months ended March 31, 2023, we recorded \$1.3 million in severance and related charges in restructuring expense.

Other **expense**. **Expense**. Major classifications of other expense were as follows:

(In thousands)	Three Months Ended December 31,		Three Months Ended March 31,		Six Months Ended March 31,	
	2023	2022	2024	2023	2024	2023
Interest expense, net	\$ (896)	\$ (826)	\$ (881)	\$ (884)	\$ (1,777)	\$ (1,710)
Foreign exchange loss	(45)	(125)	(72)	(75)	(117)	(200)
Investment income, net	539	172	460	177	999	349
Other expense, net	\$ (402)	\$ (779)	\$ (493)	\$ (782)	\$ (895)	\$ (1,561)

Interest expense, net increased in the second quarter and first quarter six months of fiscal 2024, compared to the same prior-year quarter, periods, due to higher interest rates. rates for borrowings on our revolving credit facility. Refer to "Liquidity and Capital Resources" for further discussion of financing arrangements and expectations for fiscal 2024 interest expense. Foreign currency exchange (losses) gains losses result primarily from the impact of U.S. dollar to Euro exchange rate fluctuations on certain intercompany transactions and balances. Investment income, net increased in the second quarter and first quarter six months of fiscal 2024, compared to the same prior-year quarter, periods, due to increased investments in available-for-sale securities, as well as higher interest rates.

Income **taxes**. **Taxes**. We reported income tax expense of \$(0.1) million Income taxes and income tax benefit of \$0.2 million in the first quarter of fiscal 2024 and 2023, respectively. Our our effective tax rate was (9)% were as follows:

(Dollars in thousands)	Three Months Ended March 31,		Six Months Ended March 31,	
	2024	2023	2024	2023
Income tax benefit (expense)	\$ 81	\$ (368)	\$ 19	\$ (203)
Effective tax rate	(49) %	(5) %	3 %	(1) %

Several factors impacted income taxes and 2% for the first quarter of fiscal 2024 and 2023, respectively. our effective tax rate:

- Beginning in our fiscal 2023, certain R&D costs are required to be capitalized and amortized over a five-year period under the Tax Cuts and Jobs Act enacted December 2017. This change impacts the expected U.S. federal and state income tax expense and cash taxes paid and to be paid for our fiscal 2024 and 2023.
- Since September 30, 2022, we have maintained a full valuation allowance against U.S. net deferred tax assets. As a result of the full valuation allowance, are no longer recording a tax benefit associated with U.S. pre-tax losses and incremental deferred tax assets. A valuation allowance is required to be recognized against deferred tax assets if, based on the available evidence, it is more likely than not (defined as a likelihood of more than 50%) that all or a portion of the assets will not be realized. The relevant guidance weighs available evidence such as historical cumulative taxable losses more heavily than future profitability. The valuation allowance has no impact on the availability of U.S. net deferred tax assets to offset future tax liabilities.
- Recurring items cause our effective tax rate to differ from the U.S. federal statutory rate of 21%, including foreign-derived intangible income ("FDII") deducted in the U.S., U.S. federal and Irish R&D credits, Irish and U.S. state tax rates, and excess tax benefits associated with stock-based compensation.

TABLE OF CONTENTS

Segment Operating Results

Operating results for each of our reportable segments were as follows:

(In thousands)	Three Months Ended December 31,			Three Months Ended March 31,			Six Months Ended March 31,		
	2023	2022	\$ Change	2024	2023	\$ Change	2024	2023	\$ Change

Operating loss:									
Operating income (loss):									
Medical Device	\$ (224)	\$ (7,235)	\$ 7,011	\$ 302	\$ (7,059)	\$ 7,361	\$ 78	\$ (14,294)	\$ 14,372
In Vitro Diagnostics	3,124	2,948	176	3,356	3,636	(280)	6,480	6,584	(104)
Total segment operating income (loss)	2,900	(4,287)	7,187	3,658	(3,423)	7,081	6,558	(7,710)	14,268
Corporate	(3,222)	(2,942)	(280)	(2,999)	(3,160)	161	(6,221)	(6,102)	(119)
Total operating loss	\$ (322)	\$ (7,229)	\$ 6,907						
Total operating income (loss)	\$ 659	\$ (6,583)	\$ 7,242	\$ 337	\$ (13,812)	\$ 14,149			

Medical Device. Our Medical Device business reported an operating loss income of \$(0.2) million \$0.3 million in the first second quarter of fiscal 2024, compared to \$(7.2) an operating loss of \$(7.1) million in the prior-year quarter, representing (1) 1% and (36)% of revenue, respectively. For the first six months of fiscal 2024, our Medical Device business reported operating income of \$0.1 million, compared to an operating loss of \$(14.3) million in the same prior-year period, representing 0% and (38) (37)% of revenue, respectively.

- Medical Device operating expenses, excluding product costs, decreased \$5.2 million \$3.7 million and \$8.9 million year-over-year in the second quarter and six months of fiscal 2024, respectively. The second quarter and first six months of fiscal 2023 included \$1.3 million in severance-related restructuring expense the result of the workforce restructuring implemented during the second quarter of fiscal 2024, compared to the prior-year quarter. 2023.
- R&D expenditures in our Medical Device segment declined year-over-year in the second quarter and first quarter six months of fiscal 2024 primarily as driven by lower R&D expenses associated with the result of lower SurVeil DCB due to the transition to commercialization, lower thrombectomy platform R&D expenses due to the transition to timing of development and commercialization of device products, and the spending reduction plan and workforce reduction implemented during the second quarter of fiscal 2023. SG&A expense in our Medical Device business was relatively flat in the second quarter of fiscal 2023, and 2024, compared to the timing prior-year quarter. For the first six months of certain investments in product development. fiscal 2024, SG&A expense in our Medical Device business declined modestly year-over-year in the first quarter of fiscal 2024 due to lower headcount compensation expenses, primarily as the result of the spending reduction plan and workforce reduction implemented in during the second quarter of fiscal 2023.
- Performance coating royalties and license fee revenue increased \$2.2 million and \$3.0 million year-over-year in the second quarter and first six months of fiscal 2024, respectively, primarily driven by \$1.4 million in catch-up payments in the normal course of our customers reporting sales-based royalties, customer-reported royalties in excess of estimated royalties, and continued growth in customer utilization of our Serene hydrophilic coating.

TABLE OF CONTENTS

- Medical Device product gross profit increased \$0.9 million year-over-year \$1.7 million to \$6.4 million in the first second quarter of fiscal 2024. 2024, compared to the prior-year quarter, and Medical Device product gross margins were 48.6% 58.0% and 58.6% 59.7% in the first second quarter of fiscal 2024 and 2023, respectively. Medical Device product gross profit increased \$2.6 million to \$12.2 million in the first six months of fiscal 2024, compared to the same prior-year-period, and Medical Device product gross margins were 53.1% and 59.1% in the first six months of fiscal 2024 and 2023, respectively. The year-over-year decrease in product gross margin margins was primarily driven by (i) increased sales of our vascular intervention medical devices – our SurVeil DCB, Pounce thrombectomy, and Sublime radial access products – as a proportion of total product sales, compared to the prior-year period, which had an unfavorable revenue mix impact to as these devices were not at scale, and product gross margin; and (ii) margins reflected the unfavorable impact of fixed overhead cost absorption in the first quarter of fiscal 2024, relative to the prior-year quarter, from a timing-related decrease in production volumes. In the first quarter of fiscal 2024 and 2023, product margins for our vascular intervention medical devices were impacted by the associated under-absorption of fixed costs and production inefficiencies, including expiration of inventory, associated with low production volumes that were below full scale. inefficiencies.
- Performance coating royalties and license fee revenue increased \$0.7 million to \$8.2 million in the first quarter of fiscal 2024, compared to \$7.5 million in prior-year quarter, primarily driven by growth from customers utilizing our Serene™ coating.
- Medical Device R&D services revenue increased \$0.5 million year-over-year in the first quarter six months of fiscal 2024 compared to the prior-year quarter from driven by increased volume of performance coating services. services and customer development projects.
- SurVeil DCB license fee revenue under the Abbott Agreement decreased \$0.3 million \$0.2 million and \$0.6 million year-over-year in the second quarter and

first quarter six months of fiscal 2024, compared to the prior-year quarter, respectively, driven by lower TRANSCEND clinical trial costs subsequent to receipt of PMA from the FDA for the SurVeil DCB in the third quarter of fiscal 2023.

TABLE OF CONTENTS

In Vitro Diagnostics. Our In Vitro Diagnostics business reported operating income of \$3.1 million \$3.4 million and \$2.9 million \$3.6 million in the first second quarter of fiscal 2024 and 2023, respectively, representing 45% 47% and 50% 49% of revenue, respectively. For the first six months of fiscal 2024, our In Vitro Diagnostics business reported operating income of \$6.5 million and \$6.6 million in the first six months of fiscal 2024 and 2023, respectively, representing 46% and 49% of revenue, respectively.

- IVD product gross profit increased \$0.2 million year-over-year decreased \$0.3 million to \$4.6 million in the first second quarter of fiscal 2024. 2024, compare the prior-year quarter, and IVD product gross margins were 61.4% 65.1% and 69.4% 65.7% in the second quarter of fiscal 2024 and 2023, respectively. product gross profit decreased \$0.2 million to \$8.8 million in the first quarter six months of fiscal 2024, compared to the same prior-year-period, and IVD product gross margins were 63.3% and 67.3% in the first six months of fiscal 2024 and 2023, respectively. The year-over-year decrease in product gross margin margin was driven primarily by attributable to the unfavorable impact of product mix. For the first six months of fiscal 2024, the unfavorable product mix impact was primarily related to growth in sales of relatively lower margin distributed antigen products, partly offset by leverage on higher product sales volume. products.

Corporate. The Corporate category includes expenses for administrative corporate functions, such as executive management, corporate accounting, information technology, legal, human resources and Board of Directors related fees and expenses, which we do not fully allocate to the Medical Device and IVD segments. Corporate also includes expenses, such as acquisition-related costs and litigation, which are not specific to a segment and thus not allocated to our reportable segments. The unallocated Corporate expense operating loss was \$(3.0) million and \$(3.2) million in the second quarter of fiscal 2024 and \$(2.9) 2023, respectively, and \$(6.2) million and \$(6.1) million in the first quarter six months of fiscal 2024 and 2023, respectively.

Cash Flow Operating Results

The following is a summary of cash flow results:

	Three Months Ended December 31,		Six Months Ended March 31,	
	2023	2022	2024	2023
(In thousands)				
Cash (used in) provided by:				
Operating activities	\$ (8,792)	\$ (10,802)	\$ (1,377)	\$ (16,627)
Investing activities	(8,470)	(977)	(5,673)	(1,700)
Financing activities	(1,049)	18,800	(1,454)	18,006
Effect of exchange rates on changes in cash and cash equivalents	247	411	115	503
Net change in cash and cash equivalents	\$ (18,064)	\$ 7,432	\$ (8,389)	\$ 182

Operating Activities. Cash used in operating activities was \$(8.8) \$(1.4) million in the first three six months of fiscal 2024, compared to cash used of \$(10.8) \$(16.6) million in the same prior-year period. Net loss was \$(0.8) \$(0.5) million in the first three six months of fiscal 2024, compared to \$(7.8) \$(15.6) million in the same prior-year period. Net changes in operating assets and liabilities reduced cash flows from operating activities by \$(12.4) \$(9.5) million in each of the first three six months of fiscal 2024 and reduced cash flows from operating activities by \$(7.3) million in the same prior-year period. 2023. Significant changes in operating assets and liabilities affecting cash flows during these periods included:

- Cash provided by prepaids and other assets was \$2.7 million in the first six months of fiscal 2024, compared to cash used of \$(1.6) million in the same prior-period, driven primarily by the collection of a \$3.4 million receivable in the second quarter of fiscal 2024, which had been recorded at the end of fiscal 2023 associated with the employee retention credit under the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”).
- Cash used in accounts receivable and contract assets income taxes was \$(3.4) \$(0.3) million in the first three six months of fiscal 2024, compared to cash provided of \$0.5 million in the same prior year period. The increase in cash used was primarily driven by accounts receivable and contract assets recognized

SurVeil DCB product sales to Abbott, as well as increased accounts receivable on strong year-over-year revenue growth.

24

TABLE OF CONTENTS

- Cash used in accrued liabilities was \$(7.1) million in the first three months of fiscal 2024, compared to cash used of \$(4.7) million in the same prior-year period. Cash used in both periods primarily related to annual bonus payments, and the year-over-year increase in cash used was primarily driven by the reduction in accrued expenses for compensation and SurVeil DCB clinical costs.
- Cash provided by income taxes was \$0.1million in the first three months of fiscal 2024, compared to \$2.2 million \$2.6 million in the same prior-year period, driven primarily by the receipt of a \$2.3 million tax refund under the CARES Act in the first quarter of fiscal 2023.
- Cash used in accounts receivable and contract assets was \$(4.3) million in the first six months of fiscal 2024, compared to \$(2.3) million in the same prior-year period. The year-over-year increase in cash used was primarily driven by accounts receivable and contract assets recognized on SurVeil DCB product sales to Abbott, increased contract assets recorded for growth in sales-based royalties, and increased accounts receivable on year-over-year revenue growth.
- Cash provided by used in inventories was \$0.4 million \$(0.6) million in the first three six months of fiscal 2024, compared to cash used of \$(0.9) 1.9) million in same prior-year period, as period. The year-over-year decrease in cash used was the result of active management of working capital in inventory.

25

TABLE OF CONTENTS

Investing Activities. Cash used in investing activities totaled \$(8.4) \$(5.7) million in the first three six months of fiscal 2024, compared to cash used of \$(1.0) \$(1.7) million in the same prior-year period.

- Net purchases and maturities of available-for-sale investments were a (use) source of cash totaling \$(7.8) \$(3.7) million and \$0.0 million in the first three months of fiscal 2024 and 2023, respectively.
- We invested \$0.7 million \$2.0 million and \$1.0 million \$1.7 million in property and equipment in the first three six months of fiscal 2024 and 2023, respectively.

Financing Activities. Cash (used in) provided by financing activities totaled \$(1.0) \$(1.5) million and \$18.8 million \$18.0 million in the first three six months of fiscal 2024 and 2023, respectively.

- In the first quarter of fiscal 2023, the Company entered into a new, five-year secured credit agreement with MidCap Funding IV Trust, as agent, and Mid Financial Trust, as term loan servicer and the lenders from time to time party thereto (together, "MidCap"). The Company drew \$25 million on the term loan \$5 million on the revolving credit facility at close. These proceeds were partially used to retire the Company's existing revolving credit facility with Bridgew Bank, of which \$10 million was outstanding, as well as to pay a total of \$0.7 million \$0.9 million in debt issuance costs, including fees to MidCap and legal other expenses directly associated with the financing transaction.
- In the first three six months of fiscal 2024 and 2023, we paid \$0.9 million and \$1.0 million, respectively, for acquisition of in-process R&D under the terms fiscal 2018 asset acquisition.
- In the first six months of fiscal 2024 and 2023, we paid \$1.1 million and \$0.9 million, respectively, to purchase common stock to pay employee taxes result from the vesting of stock awards and the exercise of stock options.
- In the first three six months of fiscal 2024 and 2023, we generated \$0.0 million \$0.6 million and \$0.3 million \$0.8 million, respectively, from the sale of common stock related to our stock-based compensation plans.

Liquidity and Capital Resources

As of December 31, 2023 March 31, 2024, working capital totaled \$63.3 million \$65.1 million, an increase of \$0.6 million \$2.3 million from September 30, 2023. We define working capital as current assets minus current liabilities. Cash and cash equivalents and available-for-sale investments totaled \$35.2 million \$40.9

million as of December 31, 2023 March 31, 2024, a decrease of \$10.2 million \$4.4 million from \$45.4 million as of September 30, 2023.

The Company proactively manages its access to capital to support liquidity and continued growth. On October 14, 2022, Surmodics entered into a new, five-year secured credit agreement with MidCap, consisting of up to \$100 million in term loans (\$25 million of which is at the sole discretion of MidCap) and a \$25 million revolving credit facility. At close, the Company drew \$25 million on the term loan and \$5 million on the revolving credit facility. These proceeds were partially used to retire the Company's then existing \$25 million revolving credit facility with Bridgewater Bank, of which \$10 million was outstanding. Upon closing in October 2022, the Company's cash balance increased by \$19.3 million. In fiscal 2024, the Company expects total interest expense under the credit agreement with MidCap to be approximately \$3.5 million.

- *Revolving Credit Facility.* Surmodics has access to a revolving credit facility, which provides for maximum availability of \$25 million, subject to a borrowing base. As of December 31, 2023 March 31, 2024, the outstanding balance on the revolving credit facility was \$5 million. As of December 31, 2023 March 31, 2024, additional, incremental availability on the revolving credit facility was approximately \$13.7 million \$65.0 million, based on borrowing base eligibility requirements consisting primarily of the Company's inventory, accounts receivable and contract asset balances. The revolving credit facility has an annual interest rate equal to 3.00% plus the greater of Term SOFR (as defined in the credit agreement) or 1.50%, and has a maturity date of October 1, 2027.

25

TABLE OF CONTENTS

- *Term Loan.* Surmodics has access to additional draws on the term loan if certain conditions are met. As of December 31, 2023 March 31, 2024, the outstanding principal on the term loan was \$25 million. Additional draws on the term loan may be made in increments of at least \$10 million, up to a total of \$50 million through December 31, 2024 subject to certain conditions, including having no less than \$60 million of core net revenue on a rolling four-quarter basis. An additional tranche of up to \$25 million may be available through December 31, 2024 at MidCap's sole discretion. The credit agreement with MidCap calls for interest-only payments on the term loan over the first four years, which can be extended to five years if certain criteria are met. The Company has entered into an interest rate swap arrangement with Wells Fargo, whereby the initial \$25 million borrowing on the term loan's variable base rate was fixed at 10.205% per annum for the five-year loan term. The term loan has a maturity date of October 1, 2027.

As of December 31, 2023 March 31, 2024, the Company's shelf registration statement with the SEC allows the Company to offer potentially up to \$200 million in debt securities, common stock, preferred stock, warrants, and other securities or any such combination of such securities in amounts, at prices, and on terms announced if and when the securities are ever offered. This shelf registration statement expires in May 2026.

26

TABLE OF CONTENTS

In fiscal 2024, we anticipate an increase in SG&A expenditures of between \$2.0 million \$1.0 million and \$3.0 million \$2.0 million, as well as an increase in capital expenditures. We also anticipate R&D expenses will continue to be significant in fiscal 2024, primarily related to medical device product development, including continued investment in our *Pounce* and *Sublime* product platforms. We believe that our existing cash and cash equivalents and available-for-sale investments, which totaled \$35.2 million \$40.9 million as of December 31, 2023 March 31, 2024, together with cash flow from operations and our revolving credit facility and term loans, will provide liquidity sufficient to meet our cash needs and fund our operations and planned capital expenditures for fiscal 2024. There can be no assurance, however, that our business will continue to generate cash flows at historic levels.

Beyond fiscal 2024, our cash requirements will depend extensively on the timing of market introduction and extent of market acceptance of products in our medical device product portfolio, including the *SurVeil* DCB distributed by Abbott, our exclusive distribution partner for the product. Our long-term cash requirements also will be significantly impacted by the level of our investment in commercialization of our vascular intervention device products and whether we make future corporate transactions. We cannot accurately predict our long-term cash requirements at this time. We may seek additional sources of liquidity and

capital resources, including through borrowing, debt or equity financing or corporate transactions to generate cashflow. There can be no assurance that such transactions sources will be available to us on favorable terms, if at all.

Customer Concentrations

We have agreements with a diverse base of customers and certain customers have multiple products using our technology. Abbott and Medtronic are our largest customers, comprising 27% and 10%, respectively, of our consolidated revenue for fiscal 2023. Abbott and Medtronic each comprised 19% approximately 17% and 10% 12%, respectively, of our consolidated revenue for the three six months ended December 31, 2023 March 31, 2024.

Critical Accounting Policies and Significant Estimates

Critical accounting policies are those policies that require the application of management's most challenging subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods. Critical accounting policies involve judgments and uncertainties that are sufficiently likely to result in materially different results under different assumptions and conditions. For the three six months ended December 31, 2023 March 31, 2024, there were no significant changes in our critical accounting policies. For a detailed description of our other critical accounting policies and significant estimates, see Management's Discussion and Analysis of Financial Condition and Results of Operations under Item 7 in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023.

26 27

[TABLE OF CONTENTS](#)

Forward-looking Statements

This Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our strategies for growth, including our ability to sign new license agreements, conduct clinical evaluations, and bring new products to market; the expected duration of limited market evaluations and timing of commercial launches of our products; evaluations; the development of future products and their anticipated attributes; the period over which deferred revenue related to the Abbott Agreement is expected to be recognized; our plans to evaluate our strategy for further clinical investment in the Sundance DCB; future revenue growth, our longer-term valuation-creation strategy, and our future potential; information about our product pipeline; future gross margins, operating expenses, and capital expenditures; the potential impact of a shift in revenue mix towards sales of medical devices; estimated future amortization expense; expectations regarding operating expenses and their impact on our cash flows; the period over which unrecognized compensation costs is expected to be recognized; research and development plans and expenses; the expected completion timeframe for the TRANSCEND clinical trial; anticipated cash requirements; the intended use of remaining proceeds of our borrowing under the MidCap Credit Agreement; future cash flows and sources of funding, and their ability together with existing cash, and cash equivalents, to provide liquidity sufficient to meet our cash needs and fund our operations and planned capital expenditures for fiscal 2024; statements regarding cash requirements beyond fiscal 2024; expectations regarding capital available under our secured revolving credit facility and secured term loan facilities; expectations regarding the maturity of debt; future impacts of our interest rate swap transactions; our expected interest expense in fiscal 2024 under the credit agreement with MidCap; the impact of potential lawsuits or claims; the potential impact of interest rate fluctuations on our results of operations and cash flows; the impact of potential change in raw material prices, sources of raw materials and our ability to manufacture raw materials ourselves; the potential impact on the Company of currency fluctuations; future income tax (expense) benefit; expected income tax expense and cash taxes to be paid; the likelihood that we will realize the benefits of our deferred tax assets; and the impact of the adoption of new accounting pronouncements. Without limiting the foregoing, words or phrases such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "possible," "project," "will" and similar terminology, generally identify forward-looking statements. Forward-looking statements may also represent challenging goals for us. These statements, which represent our expectations or beliefs concerning various future events, are based on current expectations that involve a number of risks and uncertainties that could cause actual results to differ materially from those of such forward-looking statements. We caution that undue reliance should not be placed on such forward-looking statements, which speak only as of the date made. Some of the

factors which could cause results to differ from those expressed in any forward-looking statement are set forth under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023. We disclaim any intent or obligation to update publicly these forward-looking statements, whether because of new information, future events or otherwise.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from our forward-looking statements, such factors include, among others:

1. ongoing operating losses, interest expense, and failure to generate cash flows from operations, which could impact expected expenditures and investment growth initiatives;
2. our reliance on a small number of significant customers, including our largest customers, Abbott and Medtronic, which causes our financial results and stock price to be subject to factors affecting those significant customers and their products, the timing of market introduction of their or competing products, product safety or efficacy concerns and intellectual property litigation impacting such customers, which could adversely affect our growth strategy and the revenue we derive;
3. our ability to successfully manufacture at commercial volumes our *SurVeil* DCB products;
4. our ability to successfully develop, obtain and maintain regulatory approval for, commercialize, and manufacture at commercial volumes our other DCB products;
5. general economic conditions that are beyond our control, such as the impacts of recessions, inflation, rising interest rates, customer mergers and acquisitions, business investment, changes in consumer confidence, and medical epidemics or pandemics such as the COVID-19 pandemic, which negatively impacted business and results of operations;
6. our ability to successfully and profitably commercialize our vascular intervention products, including our *Pounce* Venous Thrombectomy System, through our direct salesforce, or otherwise;
7. our ability to comply with the terms of our secured revolving credit facility and secured term loan facilities;

27

[TABLE OF CONTENTS](#)

8. the difficulties and uncertainties associated with the lengthy and costly new product development and foreign and domestic regulatory approval processes, such as delays, difficulties or failures in achieving acceptable clinical results or obtaining foreign or FDA marketing clearances or approvals, which may result in lost market opportunities, failure to bring new products to market or postpone or preclude product commercialization by licensees or ourselves;

28

[TABLE OF CONTENTS](#)

9. whether operating expenses that we incur related to the development and commercialization of new technologies and products are effective;
10. our ability to successfully perform product development activities, the related research and development expense impact, and governmental and regulatory compliance activities, with which we do not have extensive experience;
11. impairment of goodwill and intangible assets or the establishment of reserves against other assets on our balance sheet;
12. disruptions to our business from our plan to reduce our use of cash announced in the third quarter of fiscal 2023, the failure of such plan to achieve its objectives, or cost and expenses associated with such plan; and
13. other factors described under “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, which you are encouraged to read carefully.

Many of these factors are outside our control and knowledge and could result in increased volatility in period-to-period results. Investors are advised not to place undue reliance upon our forward-looking statements and to consult any further disclosures by us on this subject in our filings with the Securities and Exchange Commission.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our investment policy requires investments with high credit quality issuers and limits the amount of credit exposure to any one issuer. Our investments consist principally of interest-bearing corporate debt securities with varying maturity dates, which generally are less than one year. Because of the credit criteria of our investment policies, the primary market risk associated with these investments is interest rate risk. As of **December 31, 2023** **March 31, 2024**, we held **\$11.8 million** **\$7.9 million** in available-for-sale debt securities. Therefore, interest rate fluctuations relating to investments would have an insignificant impact on our results of operations or cash flows. Our policy also allows the Company to hold a substantial portion of funds in cash and cash equivalents, which are defined as financial instruments with original maturities of three months or less and may include money market instruments, certificates of deposit, repurchase agreements and commercial paper instruments.

Loans under the Midcap credit agreement bear interest at floating rates tied to Term SOFR. As a result, changes in Term SOFR can affect our results of operations and cash flows to the extent we do not have effective interest rate swap arrangements in place. On October 14, 2022, we entered into a five-year interest rate swap transaction with Wells Fargo Bank, N.A. with respect to \$25.0 million of notional value of the term loans funded under the MidCap credit agreement. The interest rate swap transaction fixes at 4.455% the one-month Term SOFR portion of interest rate under the \$25.0 million initial Term Loan funded such that the interest rate on \$25.0 million of the Term Loan will be 10.205% through its maturity. We have no other swap arrangements in place for any other loans under the Midcap credit agreement.

Management believes that a reasonable change in raw material prices would not have a material impact on future earnings or cash flows because the Company's inventory exposure is not material.

We are exposed to increasing Euro currency risk with respect to our manufacturing operations in Ireland. In addition, the contractual transfer price paid by Abbott for commercial units of our *SurVeil* DCB product is denominated in Euros. In a period where the U.S. dollar is strengthening or weakening relative to the Euro, our revenue and expenses denominated in Euro currency are translated into U.S. dollars at a lower or higher value than they would be in an otherwise constant currency exchange rate environment. All sales transactions are denominated in U.S. dollars or Euros. We generate royalties revenue from the sale of customer products in foreign jurisdictions. Royalties generated in foreign jurisdictions by customers are converted and paid in U.S. dollars per contractual terms. Substantially all of our purchasing transactions are denominated in U.S. dollars or Euros. To date, we have not entered into any foreign currency forward exchange contracts or other derivative financial instruments to hedge the effects of adverse fluctuations in foreign currency exchange rates.

28 29

[TABLE OF CONTENTS](#)

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company's management, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, referred to collectively herein as the Certifying Officers, carried out an evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of **December 31, 2023** **March 31, 2024**. Based on that evaluation, the Company's Certifying Officers concluded that, as of the end of the period covered by this report, the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) were effective to ensure that information required to be disclosed by the Company in reports that it files under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its Certifying Officers, as appropriate, to allow timely decisions regarding required disclosures.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) during the three months ended **December 31, 2023** **March 31, 2024** that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

29 **30**

[TABLE OF CONTENTS](#)

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, the Company has been involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes.

Item 1A. Risk Factors

The risks identified in our Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with the Securities and Exchange Commission on November 22, 2023, under Part I, Item 1A, “Risk Factors” could affect our financial performance and could cause our actual results for future periods to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statements made in this Quarterly Report on Form 10-Q.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

The following table presents the information with respect to purchases made by or on behalf of Surmodics, Inc. or any “affiliated purchaser” (as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of 1934), of our common stock during the three months ended **December 31, 2023** **March 31, 2024**.

	Total Number of Shares Purchased (1)	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs	Maximum Dollar Value of Shares that May Yet Be Purchased Under the Programs
Period:				
October 1 – 31, 2023	111	\$ 28.72	—	\$ 25,300,000
November 1 – 30, 2023	—	—	—	25,300,000
December 1 – 31, 2023	28,717	32.82	—	25,300,000
Total	28,828	32.80	—	

	Total Number of Shares Purchased (1)	Average Price Paid Per Share	Total Number of Shares Purchased as Part of Publicly Announced Programs	Maximum Dollar Value of Shares that May Yet Be Purchased Under the Programs
Period:				
January 1 – 31, 2024	—	\$ —	—	\$ 25,300,000
February 1 – 29, 2024	152	32.72	—	25,300,000
March 1 – 31, 2024	—	—	—	25,300,000
Total	152	32.72	—	

(1) All shares reported were delivered by employees in connection with the satisfaction of tax withholding obligations related to the vesting of shares of restri

stock.

The Company has an aggregate of \$25.3 million available for future common stock purchases under the current authorizations. The MidCap credit agreement restricts our ability to repurchase our common stock.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

30 31

TABLE OF CONTENTS

Item 6. Exhibits

EXHIBIT INDEX

Exhibit	Description
2.1	Agreement of Merger dated January 18, 2005 among Surmodics, Inc., SIRx, InnoRx, et al. — incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K dated January 24, 2005.
2.2	Share Purchase Agreement by and among Surmodics, Inc. and the shareholders of Creagh Medical Ltd. dated as of November 20, 2015 — incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K dated November 27, 2015.
2.3	Stock Purchase Agreement, dated January 8, 2016, among Surmodics, Inc. and the shareholders of NorMedix, Inc. and Gregg Sutton as Seller's Agent — incorporated by reference to Exhibit 2.1 to the Company's Form Current Report on Form 8-K filed on January 13, 2016.
2.4	Share Purchase Agreement by and among Surmodics, Inc., SurModics MD, LLC, and the shareholders of Vetex Medical Limited named therein dated as of July 2, 2021 — incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K dated July 2, 2021.
2.5	Put and Call Option Agreement by and among SurModics MD, LLC and the shareholders of Vetex Medical Limited named therein dated as of July 2, 2021 — incorporated by reference to Exhibit 2.2 to the Company's Current Report on Form 8-K dated July 2, 2021.
3.1	Restated Articles of Incorporation, as amended — incorporated by reference to Exhibit 3.1 of the Company's Quarterly Report on Form 10-Q filed on July 29, 2016.

<u>3.2</u>	<u>Restated Bylaws of Surmodics, Inc., as amended July 20, 2023 — incorporated by reference to Exhibit 3.2 of the Company's Current Report on Form 8-K filed on July 26, 2023.</u>
<u>31.1*</u>	<u>Certification of Chief Executive Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
<u>31.2*</u>	<u>Certification of Chief Financial Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>
<u>32.1*</u>	<u>Certification of Chief Executive Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
<u>32.2*</u>	<u>Certification of Chief Financial Officer pursuant to 18 U.S.C. Sec. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>
<u>101.INS*</u>	Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.
<u>101.SCH*</u>	Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents.
<u>104*</u>	Cover page formatted as Inline XBRL and contained in Exhibit 101.

* Filed herewith

3132

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

February May 1, 2024

Surmodics, Inc.

By: /s/ Timothy J. Arens
Timothy J. Arens
Senior Vice President of Finance and Chief Financial Officer

(duly authorized signatory and principal financial officer)

3233

**CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002**

I, Gary R. Maharaj, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Surmodics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: February 1, 2024 May 1, 2024

Signature: /s/ Gary R. Maharaj

Gary R. Maharaj
President and
Chief Executive Officer

Refinitiv; width: 100%; height: 20px; background-color: #f08080;">

**CERTIFICATION PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002**

I, Timothy J. Arens, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Surmodics, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated: February 1, 2024 May 1, 2024

Signature: /s/ Timothy J. Arens

Timothy J. Arens

Senior Vice President of Finance and Chief Financial Officer

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Surmodics, Inc. (the "Company") on Form 10-Q for the quarter ended **December 31, 2023** **March 31, 2024**, as filed with the Securities and Exchange Commission (the "Report"), I, Gary R. Maharaj, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: **February 1, 2024** **May 1, 2024**

Signature: /s/ Gary R. Maharaj
Gary R. Maharaj
President and
Chief Executive Officer

e; width: 100%">

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Surmodics, Inc. (the "Company") on Form 10-Q for the quarter ended **December 31, 2023** **March 31, 2024**, as filed with the Securities and Exchange Commission (the "Report"), I, Timothy J. Arens, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 1, 2024 May 1, 2024

Signature: /s/ Timothy J. Arens

Timothy J. Arens

Senior Vice President of Finance and Chief Financial Officer

DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.